1
|
Verbeek MWC, van der Velden VHJ. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia. Int J Mol Sci 2024; 25:4881. [PMID: 38732101 PMCID: PMC11084622 DOI: 10.3390/ijms25094881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2024] [Revised: 04/24/2024] [Accepted: 04/27/2024] [Indexed: 05/13/2024] Open
Abstract
Detection of minimal residual disease (MRD) is a major independent prognostic marker in the clinical management of pediatric and adult B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL), and risk stratification nowadays heavily relies on MRD diagnostics. MRD can be detected using flow cytometry based on aberrant expression of markers (antigens) during malignant B-cell maturation. Recent advances highlight the significance of novel markers (e.g., CD58, CD81, CD304, CD73, CD66c, and CD123), improving MRD identification. Second and next-generation flow cytometry, such as the EuroFlow consortium's eight-color protocol, can achieve sensitivities down to 10-5 (comparable with the PCR-based method) if sufficient cells are acquired. The introduction of targeted therapies (especially those targeting CD19, such as blinatumomab or CAR-T19) introduces several challenges for flow cytometric MRD analysis, such as the occurrence of CD19-negative relapses. Therefore, innovative flow cytometry panels, including alternative B-cell markers (e.g., CD22 and CD24), have been designed. (Semi-)automated MRD assessment, employing machine learning algorithms and clustering tools, shows promise but does not yet allow robust and sensitive automated analysis of MRD. Future directions involve integrating artificial intelligence, further automation, and exploring multicolor spectral flow cytometry to standardize MRD assessment and enhance diagnostic and prognostic robustness of MRD diagnostics in BCP-ALL.
Collapse
Affiliation(s)
| | - Vincent H. J. van der Velden
- Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
| |
Collapse
|
2
|
Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2023.12.06.570390. [PMID: 38106022 PMCID: PMC10723418 DOI: 10.1101/2023.12.06.570390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2023]
Abstract
Cancer immunotherapies have produced remarkable results in B-cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor specimens along with normal tissues to identify biologically relevant cell surface proteins that can serve as immunotherapeutic targets for neuroblastoma, an often-fatal childhood cancer of the developing nervous system. We apply this approach to human-derived cell lines (N=9) and cell/patient-derived xenograft (N=12) models of neuroblastoma. Plasma membrane-enriched mass spectrometry identified 1,461 cell surface proteins in cell lines and 1,401 in xenograft models, respectively. Additional proteogenomic analyses revealed 60 high-confidence candidate immunotherapeutic targets and we prioritized Delta-like canonical notch ligand 1 (DLK1) for further study. High expression of DLK1 directly correlated with the presence of a super-enhancer spanning the DLK1 locus. Robust cell surface expression of DLK1 was validated by immunofluorescence, flow cytometry, and immunohistochemistry. Short hairpin RNA mediated silencing of DLK1 in neuroblastoma cells resulted in increased cellular differentiation. ADCT-701, a DLK1-targeting antibody-drug conjugate (ADC), showed potent and specific cytotoxicity in DLK1-expressing neuroblastoma xenograft models. Moreover, DLK1 is highly expressed in several adult cancer types, including adrenocortical carcinoma (ACC), pheochromocytoma/paraganglioma (PCPG), hepatoblastoma, and small cell lung cancer (SCLC), suggesting potential clinical benefit beyond neuroblastoma. Taken together, our study demonstrates the utility of comprehensive cancer surfaceome characterization and credentials DLK1 as an immunotherapeutic target. Highlights Plasma membrane enriched proteomics defines surfaceome of neuroblastomaMulti-omic data integration prioritizes DLK1 as a candidate immunotherapeutic target in neuroblastoma and other cancersDLK1 expression is driven by a super-enhancer DLK1 silencing in neuroblastoma cells results in cellular differentiation ADCT-701, a DLK1-targeting antibody-drug conjugate, shows potent and specific cytotoxicity in DLK1-expressing neuroblastoma preclinical models.
Collapse
|
3
|
Das N, Gajendra S, Gupta R. Analytical Appraisal of Hematogones in B-ALL MRD Assessment Using Multidimensional Dot-Plots by Multiparametric Flow Cytometry: A Critical Review and Update. Indian J Hematol Blood Transfus 2024; 40:12-24. [PMID: 38312180 PMCID: PMC10830989 DOI: 10.1007/s12288-023-01696-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2023] [Accepted: 08/25/2023] [Indexed: 02/06/2024] Open
Abstract
The spectrum of benign B-cell precursors, known as hematogones (HGs), shows a significant morphological and immunophenotypic overlap with their malignant counterpart i.e. B-lymphoid blasts (BLBs). This results in a diagnostic dilemma in assessment of cases wherein there is a physiological preponderance of HGs and also poses a significant challenge in measurable residual disease assessment in B-cell acute lymphoblastic leukaemia. Consequently, expression patterns of various immunophenotypic markers are considered the most important tool in identification and delineation of HGs from BLBs. However, certain aspects of B-cell compartment evaluation by flow cytometric immunophenotyping and its relevance in clinical scenarios is yet to be defined precisely. This review summarizes current flowcytometric data on HGs and its discrimination from BLBs based on thorough review of literature and evaluation of in-house data. Furthermore, it focuses on the utility of an additional analytical tool i.e., radar plot for a comprehensive representation of various subsets of the B-cell compartment and their differentiation from BLBs. Supplementary Information The online version contains supplementary material available at 10.1007/s12288-023-01696-5.
Collapse
Affiliation(s)
- Nupur Das
- Laboratory Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029 India
| | - Smeeta Gajendra
- Laboratory Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029 India
| | - Ritu Gupta
- Laboratory Oncology, Dr. BRAIRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029 India
| |
Collapse
|
4
|
Cummins K, Gill S. Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Hematol Oncol Clin North Am 2023; 37:1125-1147. [PMID: 37442676 DOI: 10.1016/j.hoc.2023.06.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/15/2023]
Abstract
Up to 30% of patients with acute myeloid leukemia (AML) who undergo chimeric antigen receptor (CAR) T-cell therapy have evidence of response, although trials are highly heterogeneous. These responses are rarely deep or durable. CD123, CD33, and CLL-1 have emerged as the most common targets for CAR T cells in AML. CAR T cells against myeloid antigens cause myeloablation as well as cytokine release syndrome, although neurotoxicity is rarely seen. Future efforts should focus on AML-specific antigen discovery or engineering, and on further enhancing the activity of CAR T cells.
Collapse
Affiliation(s)
- Katherine Cummins
- Peter MacCallum Cancer Centre, University of Melbourne, 305 Grattan Street, Melbourne, VIC 3000, Australia
| | - Saar Gill
- Division of Hematology-Oncology, University of Pennsylvania Perelman School of Medicine, 8-101 Smilow Center for Translational Research, 3400 Civic Center Boulevard, Philadelphia, PA 19104, USA.
| |
Collapse
|
5
|
Sun F, Suttapitugsakul S, Wu R. Systematic characterization of extracellular glycoproteins using mass spectrometry. MASS SPECTROMETRY REVIEWS 2023; 42:519-545. [PMID: 34047389 PMCID: PMC8627532 DOI: 10.1002/mas.21708] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 05/10/2021] [Accepted: 05/13/2021] [Indexed: 05/13/2023]
Abstract
Surface and secreted glycoproteins are essential to cells and regulate many extracellular events. Because of the diversity of glycans, the low abundance of many glycoproteins, and the complexity of biological samples, a system-wide investigation of extracellular glycoproteins is a daunting task. With the development of modern mass spectrometry (MS)-based proteomics, comprehensive analysis of different protein modifications including glycosylation has advanced dramatically. This review focuses on the investigation of extracellular glycoproteins using MS-based proteomics. We first discuss the methods for selectively enriching surface glycoproteins and investigating protein interactions on the cell surface, followed by the application of MS-based proteomics for surface glycoprotein dynamics analysis and biomarker discovery. We then summarize the methods to comprehensively study secreted glycoproteins by integrating various enrichment approaches with MS-based proteomics and their applications for global analysis of secreted glycoproteins in different biological samples. Collectively, MS significantly expands our knowledge of extracellular glycoproteins and enables us to identify extracellular glycoproteins as potential biomarkers for disease detection and drug targets for disease treatment.
Collapse
Affiliation(s)
| | | | - Ronghu Wu
- School of Chemistry and Biochemistry and the Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| |
Collapse
|
6
|
Watson J, Ferguson HR, Brady RM, Ferguson J, Fullwood P, Mo H, Bexley KH, Knight D, Howell G, Schwartz JM, Smith MP, Francavilla C. Spatially resolved phosphoproteomics reveals fibroblast growth factor receptor recycling-driven regulation of autophagy and survival. Nat Commun 2022; 13:6589. [PMID: 36329028 DOI: 10.1101/2021.01.17.427038] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2021] [Accepted: 10/19/2022] [Indexed: 05/26/2023] Open
Abstract
Receptor Tyrosine Kinase (RTK) endocytosis-dependent signalling drives cell proliferation and motility during development and adult homeostasis, but is dysregulated in diseases, including cancer. The recruitment of RTK signalling partners during endocytosis, specifically during recycling to the plasma membrane, is still unknown. Focusing on Fibroblast Growth Factor Receptor 2b (FGFR2b) recycling, we reveal FGFR signalling partners proximal to recycling endosomes by developing a Spatially Resolved Phosphoproteomics (SRP) approach based on APEX2-driven biotinylation followed by phosphorylated peptides enrichment. Combining this with traditional phosphoproteomics, bioinformatics, and targeted assays, we uncover that FGFR2b stimulated by its recycling ligand FGF10 activates mTOR-dependent signalling and ULK1 at the recycling endosomes, leading to autophagy suppression and cell survival. This adds to the growing importance of RTK recycling in orchestrating cell fate and suggests a therapeutically targetable vulnerability in ligand-responsive cancer cells. Integrating SRP with other systems biology approaches provides a powerful tool to spatially resolve cellular signalling.
Collapse
Affiliation(s)
- Joanne Watson
- Division of Evolution, Infection and Genomics, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
- Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
| | - Harriet R Ferguson
- Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
| | - Rosie M Brady
- Division of Cancer Sciences, School of Medical Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, Manchester, M20 4GJ, UK
| | - Jennifer Ferguson
- Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
| | - Paul Fullwood
- Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
| | - Hanyi Mo
- Division of Evolution, Infection and Genomics, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
| | - Katherine H Bexley
- Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
| | - David Knight
- Bio-MS Core Research Facility, FBMH, The University of Manchester, M139PT, Manchester, UK
| | - Gareth Howell
- Flow Cytometry Core Research Facility, FBMH, The University of Manchester, M139PT, Manchester, UK
| | - Jean-Marc Schwartz
- Division of Evolution, Infection and Genomics, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK
| | - Michael P Smith
- Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK.
| | - Chiara Francavilla
- Division of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, M139PT, Manchester, UK.
- Manchester Breast Centre, Manchester Cancer Research Centre, The University of Manchester, M139PT, Manchester, UK.
| |
Collapse
|
7
|
Heming M, Haessner S, Wolbert J, Lu IN, Li X, Brokinkel B, Müther M, Holling M, Stummer W, Thomas C, Schulte-Mecklenbeck A, de Faria F, Stoeckius M, Hailfinger S, Lenz G, Kerl K, Wiendl H, Meyer zu Hörste G, Grauer OM. Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma. Genome Med 2022; 14:109. [PMID: 36153593 PMCID: PMC9509601 DOI: 10.1186/s13073-022-01110-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 09/05/2022] [Indexed: 11/15/2022] Open
Abstract
Background Primary central nervous system lymphoma (PCNSL) is a rare lymphoma of the central nervous system, usually of diffuse large B cell phenotype. Stereotactic biopsy followed by histopathology is the diagnostic standard. However, limited material is available from CNS biopsies, thus impeding an in-depth characterization of PCNSL. Methods We performed flow cytometry, single-cell RNA sequencing, and B cell receptor sequencing of PCNSL cells released from biopsy material, blood, and cerebrospinal fluid (CSF), and spatial transcriptomics of biopsy samples. Results PCNSL-released cells were predominantly activated CD19+CD20+CD38+CD27+ B cells. In single-cell RNA sequencing, PCNSL cells were transcriptionally heterogeneous, forming multiple malignant B cell clusters. Hyperexpanded B cell clones were shared between biopsy- and CSF- but not blood-derived cells. T cells in the tumor microenvironment upregulated immune checkpoint molecules, thereby recognizing immune evasion signals from PCNSL cells. Spatial transcriptomics revealed heterogeneous spatial organization of malignant B cell clusters, mirroring their transcriptional heterogeneity across patients, and pronounced expression of T cell exhaustion markers, co-localizing with a highly malignant B cell cluster. Conclusions Malignant B cells in PCNSL show transcriptional and spatial intratumor heterogeneity. T cell exhaustion is frequent in the PCNSL microenvironment, co-localizes with malignant cells, and highlights the potential of personalized treatments. Supplementary Information The online version contains supplementary material available at 10.1186/s13073-022-01110-1.
Collapse
|
8
|
Köhnke T, Liu X, Haubner S, Bücklein V, Hänel G, Krupka C, Solis-Mezarino V, Herzog F, Subklewe M. Integrated multiomic approach for identification of novel immunotherapeutic targets in AML. Biomark Res 2022; 10:43. [PMID: 35681175 PMCID: PMC9185890 DOI: 10.1186/s40364-022-00390-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 06/01/2022] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Immunotherapy of acute myeloid leukemia has experienced considerable advances, however novel target antigens continue to be sought after. To this end, unbiased approaches for surface protein detection are limited and integration with other data types, such as gene expression and somatic mutational burden, are poorly utilized. The Cell Surface Capture technology provides an unbiased, discovery-driven approach to map the surface proteins on cells of interest. Yet, direct utilization of primary patient samples has been limited by the considerable number of viable cells needed. METHODS Here, we optimized the Cell Surface Capture protocol to enable direct interrogation of primary patient samples and applied our optimized protocol to a set of samples from patients with acute myeloid leukemia (AML) to generate the AML surfaceome. We then further curated this AML surfaceome to exclude antigens expressed on healthy tissues and integrated mutational burden data from hematologic cancers to further enrich for targets which are likely to be essential to leukemia biology. Finally, we validated our findings in a separate cohort of AML patient samples. RESULTS Our protocol modifications allowed us to double the yield in identified proteins and increased the specificity from 54 to 80.4% compared to previous approaches. Using primary AML patient samples, we were able to identify a total of 621 surface proteins comprising the AML surfaceome. We integrated this data with gene expression and mutational burden data to curate a set of robust putative target antigens. Seventy-six proteins were selected as potential candidates for further investigation of which we validated the most promising novel candidate markers, and identified CD148, ITGA4 and Integrin beta-7 as promising targets in AML. Integrin beta-7 showed the most promising combination of expression in patient AML samples, and low or absent expression on healthy hematopoietic tissue. CONCLUSION Taken together, we demonstrate the feasibility of a highly optimized surfaceome detection method to interrogate the entire AML surfaceome directly from primary patient samples and integrate this data with gene expression and mutational burden data to achieve a robust, multiomic target identification platform. This approach has the potential to accelerate the unbiased target identification for immunotherapy of AML.
Collapse
Affiliation(s)
- Thomas Köhnke
- Department of Medicine III, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.,Laboratory for Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | - Xilong Liu
- Laboratory for Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | - Sascha Haubner
- Department of Medicine III, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.,Laboratory for Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | - Veit Bücklein
- Department of Medicine III, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.,Laboratory for Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | - Gerulf Hänel
- Department of Medicine III, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany.,Laboratory for Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | - Christina Krupka
- Laboratory for Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany
| | | | - Franz Herzog
- Department of Biochemistry, Gene Center, LMU Munich, Munich, Germany
| | - Marion Subklewe
- Department of Medicine III, University Hospital, LMU Munich, Marchioninistr 15, 81377, Munich, Germany. .,Laboratory for Translational Cancer Immunology, Gene Center Munich, LMU Munich, Munich, Germany. .,German Cancer Consortium (DKTK), Heidelberg, Germany. .,German Cancer Research Center (DKFZ), Heidelberg, Germany.
| |
Collapse
|
9
|
Aust G, Zheng L, Quaas M. To Detach, Migrate, Adhere, and Metastasize: CD97/ADGRE5 in Cancer. Cells 2022; 11:cells11091538. [PMID: 35563846 PMCID: PMC9101421 DOI: 10.3390/cells11091538] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 04/26/2022] [Accepted: 05/02/2022] [Indexed: 11/16/2022] Open
Abstract
Tumorigenesis is a multistep process, during which cells acquire a series of mutations that lead to unrestrained cell growth and proliferation, inhibition of cell differentiation, and evasion of cell death. Growing tumors stimulate angiogenesis, providing them with nutrients and oxygen. Ultimately, tumor cells invade the surrounding tissue and metastasize; a process responsible for about 90% of cancer-related deaths. Adhesion G protein-coupled receptors (aGPCRs) modulate the cellular processes closely related to tumor cell biology, such as adhesion and detachment, migration, polarity, and guidance. Soon after first being described, individual human aGPCRs were found to be involved in tumorigenesis. Twenty-five years ago, CD97/ADGRE5 was discovered to be induced in one of the most severe tumors, dedifferentiated anaplastic thyroid carcinoma. After decades of research, the time has come to review our knowledge of the presence and function of CD97 in cancer. In summary, CD97 is obviously induced or altered in many tumor entities; this has been shown consistently in nearly one hundred published studies. However, its high expression at circulating and tumor-infiltrating immune cells renders the systemic targeting of CD97 in tumors difficult.
Collapse
Affiliation(s)
- Gabriela Aust
- Research Laboratories of the Clinic of Visceral, Transplantation, Thoracic, and Vascular Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany;
- Research Laboratories of the Clinic of Orthopedics, Traumatology and Plastic Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany;
| | - Leyu Zheng
- Research Laboratories of the Clinic of Orthopedics, Traumatology and Plastic Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany;
| | - Marianne Quaas
- Research Laboratories of the Clinic of Visceral, Transplantation, Thoracic, and Vascular Surgery, Medical School, University Hospital Leipzig, Leipzig University, 04103 Leipzig, Germany;
- Correspondence:
| |
Collapse
|
10
|
Yakymiv Y, Augeri S, Bracci C, Marchisio S, Aydin S, D'Ardia S, Massaia M, Ferrero E, Ortolan E, Funaro A. CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. Sci Rep 2021; 11:21230. [PMID: 34707185 PMCID: PMC8551154 DOI: 10.1038/s41598-021-00733-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 10/18/2021] [Indexed: 12/17/2022] Open
Abstract
CD157/BST-1 (a member of the ADP-ribosyl cyclase family) is expressed at variable levels in 97% of patients with acute myeloid leukemia (AML), and is currently under investigation as a target for antibody-based immunotherapy. We used peripheral blood and bone marrow samples from patients with AML to analyse the impact of CD157-directed antibodies in AML survival and in response to cytarabine (AraC) ex vivo. The study was extended to the U937, THP1 and OCI-AML3 AML cell lines of which we engineered CD157-low versions by shRNA knockdown. CD157-targeting antibodies enhanced survival, decreased apoptosis and reduced AraC toxicity in AML blasts and cell lines. CD157 signaling activated the PI3K/AKT/mTOR and MAPK/ERK pathways and increased expression of Mcl-1 and Bcl-XL anti-apoptotic proteins, while decreasing expression of Bax pro-apoptotic protein, thus preventing Caspase-3 activation. The primary CD157-mediated anti-apoptotic mechanism was Bak sequestration by Mcl-1. Indeed, the Mcl-1-specific inhibitor S63845 restored apoptosis by disrupting the interaction of Mcl-1 with Bim and Bak and significantly increased AraC toxicity in CD157-high but not in CD157-low AML cells. This study provides a new role for CD157 in AML cell survival, and indicates a potential role of CD157 as a predictive marker of response to therapies exploiting Mcl-1 pharmacological inhibition.
Collapse
Affiliation(s)
- Yuliya Yakymiv
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126, Torino, Italy
| | - Stefania Augeri
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126, Torino, Italy
| | - Cristiano Bracci
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126, Torino, Italy
| | - Sara Marchisio
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126, Torino, Italy
| | - Semra Aydin
- Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University of Bonn, Bonn, Germany
| | - Stefano D'Ardia
- Division of Hematology, Department of Oncology, Presidio Molinette, AOU Città della Salute e della Scienza, Torino, Italy
| | | | - Enza Ferrero
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126, Torino, Italy
| | - Erika Ortolan
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126, Torino, Italy.
| | - Ada Funaro
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126, Torino, Italy.
| |
Collapse
|
11
|
Syafruddin SE, Nazarie WFWM, Moidu NA, Soon BH, Mohtar MA. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature. BMC Cancer 2021; 21:850. [PMID: 34301218 PMCID: PMC8306276 DOI: 10.1186/s12885-021-08591-0] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 07/05/2021] [Indexed: 12/11/2022] Open
Abstract
Background Glioblastoma multiforme (GBM) is a highly lethal, stage IV brain tumour with a prevalence of approximately 2 per 10,000 people globally. The cell surface proteins or surfaceome serve as information gateway in many oncogenic signalling pathways and are important in modulating cancer phenotypes. Dysregulation in surfaceome expression and activity have been shown to promote tumorigenesis. The expression of GBM surfaceome is a case in point; OMICS screening in a cell-based system identified that this sub-proteome is largely perturbed in GBM. Additionally, since these cell surface proteins have ‘direct’ access to drugs, they are appealing targets for cancer therapy. However, a comprehensive GBM surfaceome landscape has not been fully defined yet. Thus, this study aimed to define GBM-associated surfaceome genes and identify key cell-surface genes that could potentially be developed as novel GBM biomarkers for therapeutic purposes. Methods We integrated the RNA-Seq data from TCGA GBM (n = 166) and GTEx normal brain cortex (n = 408) databases to identify the significantly dysregulated surfaceome in GBM. This was followed by an integrative analysis that combines transcriptomics, proteomics and protein-protein interaction network data to prioritize the high-confidence GBM surfaceome signature. Results Of the 2381 significantly dysregulated genes in GBM, 395 genes were classified as surfaceome. Via the integrative analysis, we identified 6 high-confidence GBM molecular signature, HLA-DRA, CD44, SLC1A5, EGFR, ITGB2, PTPRJ, which were significantly upregulated in GBM. The expression of these genes was validated in an independent transcriptomics database, which confirmed their upregulated expression in GBM. Importantly, high expression of CD44, PTPRJ and HLA-DRA is significantly associated with poor disease-free survival. Last, using the Drugbank database, we identified several clinically-approved drugs targeting the GBM molecular signature suggesting potential drug repurposing. Conclusions In summary, we identified and highlighted the key GBM surface-enriched repertoires that could be biologically relevant in supporting GBM pathogenesis. These genes could be further interrogated experimentally in future studies that could lead to efficient diagnostic/prognostic markers or potential treatment options for GBM. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08591-0.
Collapse
Affiliation(s)
- Saiful Effendi Syafruddin
- UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia
| | | | - Nurshahirah Ashikin Moidu
- UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia
| | - Bee Hong Soon
- Department of Surgery, Neurosurgery Division, Faculty of Medicine, Universiti Kebangsaan Malaysia, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia
| | - M Aiman Mohtar
- UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Bandar Tun Razak, Cheras, 56000, Kuala Lumpur, Malaysia.
| |
Collapse
|
12
|
Chatterjee G, Dudakia V, Ghogale S, Deshpande N, Girase K, Chaturvedi A, Shetty D, Senger M, Jain H, Bagal B, Bonda A, Punatar S, Gokarn A, Khattry N, Patkar NV, Gujral S, Subramanian PG, Tembhare PR. Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment. Int J Lab Hematol 2021; 43:990-999. [PMID: 33432783 DOI: 10.1111/ijlh.13456] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 10/27/2020] [Accepted: 12/14/2020] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Many new markers are being evaluated to increase the sensitivity and applicability of multicolor flow cytometry (MFC)-based measurable residual disease (MRD) monitoring. However, most of the studies are limited to childhood B-cell lymphoblastic leukemia/lymphoma (B-ALL), and reports in adult B-ALL are extremely scarce and limited to small cohorts. We studied the expression of CD304/neuropilin-1 in a large cohort of adult B-ALL patients and evaluated its practical utility in MFC-based MRD analysis. METHODS CD304 was studied in blasts from adult B-ALL patients and normal precursor B cells (NPBC) from non-B-ALL bone marrow samples using MFC. CD304 expression intensity and pattern were studied with normalized-mean fluorescent intensity (nMFI) and coefficient of variation of immunofluorescence (CVIF), respectively. MFC-based MRD was performed at end of induction (EOI; day-35), end of consolidation (EOC; day 78-80), and subsequent follow-up (SFU) time points. RESULTS CD304 was positive in 120/214(56.07%) and was significantly associated with BCR-ABL1 fusion (P = .001). EOI-MRD and EOC-MRD were positive in 129/214(60.3%) and 50/81(61.72%), respectively. CD304 was positive in a significant percentage of EOI (48%, 62/129) and EOC (52%, 26/50) MRD-positive B-ALL samples. Its expression was retained, lost, and gained in 73.7%, 26.3%, and 11.3% of EOI-MRD and 85.7%, 14.3%, and none of EOC-MRD samples, respectively. Low-level MRD (<0.01%) was detectable in 34 of all (EOI + EOC + SFU = 189) MRD-positive samples, and CD304 was found useful in 50% of these samples. CONCLUSION CD304 is commonly expressed in adult B-ALL and clearly distinguish B-ALL blasts from normal precursor B cells. It is a stable MRD marker and distinctly useful in the detection of MFC-based MRD monitoring, especially in high-sensitivity MRD assay.
Collapse
Affiliation(s)
- Gaurav Chatterjee
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Vishesh Dudakia
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Sitaram Ghogale
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Nilesh Deshpande
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Karishma Girase
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Anumeha Chaturvedi
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Dhanlaxmi Shetty
- Department of Department of Cancer Cytogenetics, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Manju Senger
- Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Hasmukh Jain
- Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Bhausaheb Bagal
- Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Avinash Bonda
- Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Sachin Punatar
- Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Anant Gokarn
- Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Navin Khattry
- Department of Medical Oncology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Nikhil V Patkar
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Sumeet Gujral
- Department of Pathology, Tata Memorial Center, HBNI University, Mumbai, India
| | - Papagudi G Subramanian
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| | - Prashant R Tembhare
- Department of Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, India
| |
Collapse
|
13
|
Broto GE, Corrêa S, Trigo FC, Dos Santos EC, Tomiotto-Pelissier F, Pavanelli WR, Silveira GF, Abdelhay E, Panis C. Comparative Analysis of Systemic and Tumor Microenvironment Proteomes From Children With B-Cell Acute Lymphocytic Leukemia at Diagnosis and After Induction Treatment. Front Oncol 2021; 10:550213. [PMID: 33381445 PMCID: PMC7769010 DOI: 10.3389/fonc.2020.550213] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 11/06/2020] [Indexed: 12/03/2022] Open
Abstract
Among the childhood diseases, B-cell acute lymphocytic leukemia (B-ALL) is the most frequent type of cancer. Despite recent advances concerning disease treatment, cytotoxic chemotherapy remains the first line of treatment in several countries, and the modifications induced by such drugs in the organism are still poorly understood. In this context, the present study provided a comparative high-throughput proteomic analysis of the cumulative changes induced by chemotherapeutic drugs used in the induction phase of B-ALL treatment in both peripheral blood (PB) and bone marrow compartment (BM) samples. To reach this goal, PB and BM plasma samples were comparatively analyzed by using label-free proteomics at two endpoints: at diagnosis (D0) and the end of the cumulative induction phase treatment (D28). Proteomic data was available via ProteomeXchange with identifier PXD021584. The resulting differentially expressed proteins were explored by bioinformatics approaches aiming to identify the main gene ontology processes, pathways, and transcription factors altered by chemotherapy, as well as to understand B-ALL biology in each compartment at D0. At D0, PB was characterized as a pro-inflammatory environment, with the involvement of several downregulated coagulation proteins as KNG, plasmin, and plasminogen. D28 was characterized predominantly by immune response-related processes and the super expression of the transcription factor IRF3 and transthyretin. RUNX1 was pointed out as a common transcription factor found in both D0 and D28. We chose to validate the proteins transthyretin and interferon-gamma (IFN-γ) by commercial kits and expressed the results as PB/BM ratios. Transthyretin ratio was augmented after induction chemotherapy, while IFN-γ was reduced at the end of the treatment. Considering that most of these proteins were not yet described in B-ALL literature, these findings added to understanding disease biology at diagnosis and highlighted a possible role for transthyretin and IFN-γ as mechanisms related to disease resolution.
Collapse
Affiliation(s)
- Geise Ellen Broto
- Programa de Pós-graduação em Patologia Clínica e Laboratorial, Universidade Estadual de Londrina, Londrina, Brazil.,Laboratório de Biologia de Tumores, Universidade Estadual do Oeste do Paraná, UNIOESTE, Francisco Beltrão, Brazil
| | - Stephany Corrêa
- Laboratório de Células-Tronco, Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | | | - Everton Cruz Dos Santos
- Laboratório de Células-Tronco, Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | | | - Wander Rogério Pavanelli
- Programa de Pós-graduação em Patologia Experimental Universidade Estadual de Londrina, Londrina, Brazil
| | | | - Eliana Abdelhay
- Laboratório de Células-Tronco, Centro de Transplante de Medula Óssea (CEMO), Instituto Nacional de Câncer, Rio de Janeiro, Brazil
| | - Carolina Panis
- Programa de Pós-graduação em Patologia Clínica e Laboratorial, Universidade Estadual de Londrina, Londrina, Brazil.,Laboratório de Biologia de Tumores, Universidade Estadual do Oeste do Paraná, UNIOESTE, Francisco Beltrão, Brazil.,Programa de Pós-graduação em Patologia Experimental Universidade Estadual de Londrina, Londrina, Brazil.,Programa de Pós-Graduação em Ciências Aplicadas à Saúde, Universidade Estadual do Oeste do Paraná, UNIOESTE, Francisco Beltrão, Brazil
| |
Collapse
|
14
|
Bornhauser B, Cario G, Rinaldi A, Risch T, Rodriguez Martinez V, Schütte M, Warnatz HJ, Scheidegger N, Mirkowska P, Temperli M, Möller C, Schumich A, Dworzak M, Attarbaschi A, Brüggemann M, Ritgen M, Mejstrikova E, Hofmann A, Buldini B, Scarparo P, Basso G, Maglia O, Gaipa G, Skoblyn TL, Te Kronnie G, Vendramini E, Panzer-Grümayer R, Barz MJ, Marovca B, Hauri-Hohl M, Niggli F, Eckert C, Schrappe M, Stanulla M, Zimmermann M, Wollscheid B, Yaspo ML, Bourquin JP. The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Adv 2020; 4:4052-4064. [PMID: 32853382 PMCID: PMC7479947 DOI: 10.1182/bloodadvances.2019000938] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Accepted: 05/29/2020] [Indexed: 12/13/2022] Open
Abstract
Most relapses of acute lymphoblastic leukemia (ALL) occur in patients with a medium risk (MR) for relapse on the Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Münster (AIEOP-BFM) ALL protocol, based on persistence of minimal residual disease (MRD). New insights into biological features that are associated with MRD are needed. Here, we identify the glycosylphosphatidylinositol-anchored cell surface protein vanin-2 (VNN2; GPI-80) by charting the cell surface proteome of MRD very high-risk (HR) B-cell precursor (BCP) ALL using a chemoproteomics strategy. The correlation between VNN2 transcript and surface protein expression enabled a retrospective analysis (ALL-BFM 2000; N = 770 cases) using quantitative polymerase chain reaction to confirm the association of VNN2 with MRD and independent prediction of worse outcome. Using flow cytometry, we detected VNN2 expression in 2 waves, in human adult bone marrow stem and progenitor cells and in the mature myeloid compartment, in line with proposed roles for fetal hematopoietic stem cells and inflammation. Prospective validation by flow cytometry in the ongoing clinical trial (AIEOP-BFM 2009) identified 10% (103/1069) of VNN2+ BCP ALL patients at first diagnosis, primarily in the MRD MR (48/103, 47%) and HR (37/103, 36%) groups, across various cytogenetic subtypes. We also detected frequent mutations in epigenetic regulators in VNN2+ ALLs, including histone H3 methyltransferases MLL2, SETD2, and EZH2 and demethylase KDM6A. Inactivation of the VNN2 gene did not impair leukemia repopulation capacity in xenografts. Taken together, VNN2 marks a cellular state of increased resistance to chemotherapy that warrants further investigations. Therefore, this marker should be included in diagnostic flow cytometry panels.
Collapse
Affiliation(s)
- Beat Bornhauser
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Gunnar Cario
- Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Anna Rinaldi
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Thomas Risch
- Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - Virginia Rodriguez Martinez
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | | | - Hans-Jörg Warnatz
- Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - Nastassja Scheidegger
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Paulina Mirkowska
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Martina Temperli
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Claudia Möller
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Angela Schumich
- St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna, Austria
| | - Michael Dworzak
- St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna, Austria
| | - Andishe Attarbaschi
- St. Anna Children's Hospital and Children's Cancer Research Institute, Vienna, Austria
| | - Monika Brüggemann
- Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Mathias Ritgen
- Department of Hematology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Ester Mejstrikova
- Department of Pediatric Hematology and Oncology, Charles University Hospital Motol, Prague, Czech Republic
| | - Andreas Hofmann
- Department of Health Sciences and Technology and Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
| | - Barbara Buldini
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - Pamela Scarparo
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - Giuseppe Basso
- Department of Women's and Children's Health, University of Padova, Padova, Italy
- Italian Institute for Genomic Medicine, Turin, Italy
| | - Oscar Maglia
- M. Tettamanti Research Center, University of Milano Bicocca, Monza, Italy
| | - Giuseppe Gaipa
- M. Tettamanti Research Center, University of Milano Bicocca, Monza, Italy
| | - Tessa-Lara Skoblyn
- Pediatric Hematology and Oncology, Charité University Hospital, Berlin, Germany
| | - Geertruij Te Kronnie
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | - Elena Vendramini
- Department of Women's and Children's Health, University of Padova, Padova, Italy
| | | | - Malwine Jeanette Barz
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Blerim Marovca
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Mathias Hauri-Hohl
- Department of Stem Cell Transplantation, University Children's Hospital Zurich, Zurich, Switzerland; and
| | - Felix Niggli
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| | - Cornelia Eckert
- Pediatric Hematology and Oncology, Charité University Hospital, Berlin, Germany
| | - Martin Schrappe
- Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Martin Stanulla
- Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - Martin Zimmermann
- Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
| | - Bernd Wollscheid
- Department of Health Sciences and Technology and Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
| | - Marie-Laure Yaspo
- Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - Jean-Pierre Bourquin
- Department of Oncology, University Children's Hospital Zurich and Children's Research Center, Zurich, Switzerland
| |
Collapse
|
15
|
Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia. Cancers (Basel) 2020; 12:cancers12082264. [PMID: 32823516 PMCID: PMC7463512 DOI: 10.3390/cancers12082264] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 08/03/2020] [Accepted: 08/10/2020] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Based on previous retrospective results, we investigated the association of coagulation FXIII subunit A (FXIII-A) expression pattern on survival and correlations with known prognostic factors of B-cell progenitor (BCP) childhood acute lymphoblastic leukemia (ALL) as a pilot study of the prospective multi-center BFM ALL-IC 2009 clinical trial. METHODS The study included four national centers (n = 408). Immunophenotyping by flow cytometry and cytogenetic analysis were performed by standard methods. Copy number alteration was studied in a subset of patients (n = 59). Survival rates were estimated by Kaplan-Meier analysis. Correlations between FXIII-A expression patterns and risk factors were investigated with Cox and logistic regression models. RESULTS Three different patterns of FXIII-A expression were observed: negative (<20%), dim (20-79%), and bright (≥80%). The FXIII-A dim expression group had significantly higher 5-year event-free survival (EFS) (93%) than the FXIII-A negative (70%) and FXIII-A bright (61%) groups. Distribution of intermediate genetic risk categories and the "B-other" genetic subgroup differed significantly between the FXIII-A positive and negative groups. Multivariate logistic regression confirmed independent association between the FXIII-A negative expression characteristics and the prevalence of intermediate genetic risk group. CONCLUSIONS FXIII-A negativity is associated with dismal survival in children with BCP-ALL and is an indicator for the presence of unfavorable genetic alterations.
Collapse
|
16
|
Oldham RAA, Faber ML, Keppel TR, Buchberger AR, Waas M, Hari P, Gundry RL, Medin JA. Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets. J Immunother Cancer 2020; 8:e000915. [PMID: 32771993 PMCID: PMC7418848 DOI: 10.1136/jitc-2020-000915] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/02/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in the bone marrow. While recent advances in treatment for MM have improved patient outcomes, the 5-year survival rate remains ~50%. A better understanding of the MM cell surface proteome could facilitate development of new directed therapies and assist in stratification and monitoring of patient outcomes. METHODS In this study, we first used a mass spectrometry (MS)-based discovery-driven cell surface capture (CSC) approach to map the cell surface N-glycoproteome of MM cell lines. Next, we developed targeted MS assays, and applied these to cell lines and primary patient samples to refine the list of candidate tumor markers. Candidates of interest detected by MS on MM patient samples were further validated using flow cytometry (FCM). RESULTS We identified 696 MM cell surface N-glycoproteins by CSC, and developed 73 targeted MS detection assays. MS-based validation using primary specimens detected 30 proteins with significantly higher abundance in patient MM cells than controls. Nine of these proteins were identified as potential immunotherapeutic targets, including five that were validated by FCM, confirming their expression on the cell surface of primary MM patient cells. CONCLUSIONS This MM surface N-glycoproteome will be a valuable resource in the development of biomarkers and therapeutics. Further, we anticipate that our targeted MS assays will have clinical benefit for the diagnosis, stratification, and treatment of MM patients.
Collapse
Affiliation(s)
- Robyn A A Oldham
- Medical Biophysics, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada
- Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Mary L Faber
- Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Theodore R Keppel
- Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- Center for Biomedical Mass Spectrometry Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Amanda R Buchberger
- Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- Center for Biomedical Mass Spectrometry Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Matthew Waas
- Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- Center for Biomedical Mass Spectrometry Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Parameswaran Hari
- Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Rebekah L Gundry
- Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- Center for Biomedical Mass Spectrometry Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| | - Jeffrey A Medin
- Medical Biophysics, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada
- Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| |
Collapse
|
17
|
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Schiöth HB. Opportunities and challenges for drug discovery in modulating Adhesion G protein-coupled receptor (GPCR) functions. Expert Opin Drug Discov 2020; 15:1291-1307. [DOI: 10.1080/17460441.2020.1791075] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Andrey D. Bondarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Misty M. Attwood
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Jörgen Jonsson
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
| | - Vladimir N. Chubarev
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vadim V. Tarasov
- Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
- Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Helgi B. Schiöth
- Department Of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden
- Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
18
|
Vais H, Wang M, Mallilankaraman K, Payne R, McKennan C, Lock JT, Spruce LA, Fiest C, Chan MYL, Parker I, Seeholzer SH, Foskett JK, Mak DOD. ER-luminal [Ca 2+] regulation of InsP 3 receptor gating mediated by an ER-luminal peripheral Ca 2+-binding protein. eLife 2020; 9:e53531. [PMID: 32420875 PMCID: PMC7259957 DOI: 10.7554/elife.53531] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2019] [Accepted: 05/15/2020] [Indexed: 12/17/2022] Open
Abstract
Modulating cytoplasmic Ca2+ concentration ([Ca2+]i) by endoplasmic reticulum (ER)-localized inositol 1,4,5-trisphosphate receptor (InsP3R) Ca2+-release channels is a universal signaling pathway that regulates numerous cell-physiological processes. Whereas much is known regarding regulation of InsP3R activity by cytoplasmic ligands and processes, its regulation by ER-luminal Ca2+ concentration ([Ca2+]ER) is poorly understood and controversial. We discovered that the InsP3R is regulated by a peripheral membrane-associated ER-luminal protein that strongly inhibits the channel in the presence of high, physiological [Ca2+]ER. The widely-expressed Ca2+-binding protein annexin A1 (ANXA1) is present in the nuclear envelope lumen and, through interaction with a luminal region of the channel, can modify high-[Ca2+]ER inhibition of InsP3R activity. Genetic knockdown of ANXA1 expression enhanced global and local elementary InsP3-mediated Ca2+ signaling events. Thus, [Ca2+]ER is a major regulator of InsP3R channel activity and InsP3R-mediated [Ca2+]i signaling in cells by controlling an interaction of the channel with a peripheral membrane-associated Ca2+-binding protein, likely ANXA1.
Collapse
Affiliation(s)
- Horia Vais
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| | - Min Wang
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| | - Karthik Mallilankaraman
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| | - Riley Payne
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| | - Chris McKennan
- Department of Statistics, University of PittsburghPittsburghUnited States
| | - Jeffrey T Lock
- Department of Neurobiology and Behavior, University of CaliforniaIrvineUnited States
| | - Lynn A Spruce
- Proteomics Core Facility, The Children’s Hospital of PhiladelphiaPhiladelphiaUnited States
| | - Carly Fiest
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| | - Matthew Yan-lok Chan
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| | - Ian Parker
- Department of Neurobiology and Behavior, University of CaliforniaIrvineUnited States
- Department of Physiology and Biophysics, University of CaliforniaIrvineUnited States
| | - Steven H Seeholzer
- Proteomics Core Facility, The Children’s Hospital of PhiladelphiaPhiladelphiaUnited States
| | - J Kevin Foskett
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
- Department of Cell and Developmental Biology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| | - Don-On Daniel Mak
- Department of Physiology, Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUnited States
| |
Collapse
|
19
|
Yakymiv Y, Augeri S, Fissolo G, Peola S, Bracci C, Binaschi M, Bellarosa D, Pellacani A, Ferrero E, Ortolan E, Funaro A. CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia. Cells 2019; 8:cells8121580. [PMID: 31817547 PMCID: PMC6952987 DOI: 10.3390/cells8121580] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 11/29/2019] [Accepted: 12/04/2019] [Indexed: 12/12/2022] Open
Abstract
Human CD157/BST-1 and CD38 are dual receptor-enzymes derived by gene duplication that belong to the ADP ribosyl cyclase gene family. First identified over 30 years ago as Mo5 myeloid differentiation antigen and 10 years later as Bone Marrow Stromal Cell Antigen 1 (BST-1), CD157 proved not to be restricted to the myeloid compartment and to have a diversified functional repertoire ranging from immunity to cancer and metabolism. Despite being a NAD+-metabolizing ectoenzyme anchored to the cell surface through a glycosylphosphatidylinositol moiety, the functional significance of human CD157 as an enzyme remains unclear, while its receptor role emerged from its discovery and has been clearly delineated with the identification of its high affinity binding to fibronectin. The aim of this review is to provide an overview of the immunoregulatory functions of human CD157/BST-1 in physiological and pathological conditions. We then focus on CD157 expression in hematological tumors highlighting its emerging role in the interaction between acute myeloid leukemia and extracellular matrix proteins and its potential utility for monoclonal antibody targeted therapy in this disease.
Collapse
MESH Headings
- ADP-ribosyl Cyclase/antagonists & inhibitors
- ADP-ribosyl Cyclase/chemistry
- ADP-ribosyl Cyclase/metabolism
- Adaptive Immunity
- Antigens, CD/chemistry
- Antigens, CD/metabolism
- Antineoplastic Agents, Immunological/pharmacology
- Antineoplastic Agents, Immunological/therapeutic use
- Biomarkers, Tumor
- Disease Susceptibility
- Enzyme Activation
- GPI-Linked Proteins/antagonists & inhibitors
- GPI-Linked Proteins/chemistry
- GPI-Linked Proteins/metabolism
- Humans
- Immunity, Innate
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Myeloid, Acute/etiology
- Leukemia, Myeloid, Acute/metabolism
- Leukemia, Myeloid, Acute/pathology
- Models, Molecular
- Molecular Targeted Therapy
- Myeloid Cells/cytology
- Myeloid Cells/drug effects
- Myeloid Cells/metabolism
- Protein Conformation
- Structure-Activity Relationship
- Substrate Specificity
- Tissue Distribution
Collapse
Affiliation(s)
- Yuliya Yakymiv
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
| | - Stefania Augeri
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
| | - Giulia Fissolo
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
| | - Silvia Peola
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
| | - Cristiano Bracci
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
| | - Monica Binaschi
- Department of Experimental and Translational Oncology, Menarini Ricerche S.p.A, 00071 Pomezia, Rome, Italy; (M.B.); (D.B.)
| | - Daniela Bellarosa
- Department of Experimental and Translational Oncology, Menarini Ricerche S.p.A, 00071 Pomezia, Rome, Italy; (M.B.); (D.B.)
| | | | - Enza Ferrero
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
| | - Erika Ortolan
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
| | - Ada Funaro
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy; (Y.Y.); (S.A.); (G.F.); (S.P.); (C.B.); (E.F.); (E.O.)
- Correspondence: ; Tel.: +39-011-6705988
| |
Collapse
|
20
|
Vaisitti T, Arruga F, Guerra G, Deaglio S. Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets. Front Immunol 2019; 10:2301. [PMID: 31636635 PMCID: PMC6788384 DOI: 10.3389/fimmu.2019.02301] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Accepted: 09/11/2019] [Indexed: 12/11/2022] Open
Abstract
Leukemia develops as the result of intrinsic features of the transformed cell, such as gene mutations and derived oncogenic signaling, and extrinsic factors, such as a tumor-friendly, immunosuppressed microenvironment, predominantly in the lymph nodes and the bone marrow. There, high extracellular levels of nucleotides, mainly NAD+ and ATP, are catabolized by different ectonucleotidases, which can be divided in two families according to substrate specificity: on one side those that metabolize NAD+, including CD38, CD157, and CD203a; on the other, those that convert ATP, namely CD39 (and other ENTPDases) and CD73. They generate products that modulate intracellular calcium levels and that activate purinergic receptors. They can also converge on adenosine generation with profound effects, both on leukemic cells, enhancing chemoresistance and homing, and on non-malignant immune cells, polarizing them toward tolerance. This review will first provide an overview of ectonucleotidases expression within the immune system, in physiological and pathological conditions. We will then focus on different hematological malignancies, discussing their role as disease markers and possibly pathogenic agents. Lastly, we will describe current efforts aimed at therapeutic targeting of this family of enzymes.
Collapse
Affiliation(s)
- Tiziana Vaisitti
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - Francesca Arruga
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - Giulia Guerra
- Department of Medical Sciences, University of Turin, Turin, Italy
| | - Silvia Deaglio
- Department of Medical Sciences, University of Turin, Turin, Italy
| |
Collapse
|
21
|
Citalan-Madrid AF, Cabral-Pacheco GA, Martinez-de-Villarreal LE, Villarreal-Martinez L, Ibarra-Ramirez M, Garza-Veloz I, Cardenas-Vargas E, Marino-Martinez I, Martinez-Fierro ML. Proteomic tools and new insights for the study of B-cell precursor acute lymphoblastic leukemia. ACTA ACUST UNITED AC 2019; 24:637-650. [PMID: 31514680 DOI: 10.1080/16078454.2019.1664127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a hematological malignancy of immature B-cell precursors, affecting children more often than adults. The etiology of BCP-ALL is still unknown, but environmental factors, sex, race or ethnicity, and genomic alterations influence the development of the disease. Tools based on protein detection, such as flow cytometry, mass spectrometry, mass cytometry and reverse phase protein array, represent an opportunity to investigate BCP-ALL pathogenesis and to identify new biomarkers of disease. This review aims to document the recent advancements with respect to applications of proteomic technologies to study mechanisms of leukemogenesis, how this information could be used in the discovery of biological targets, and finally we describe the challenges of application of proteomic tools for the approach of BCP-ALL.
Collapse
Affiliation(s)
- Alí F Citalan-Madrid
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico
| | - Griselda A Cabral-Pacheco
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico.,Program of Doctorate in Sciences with Orientation in Molecular Medicine, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico
| | | | - Laura Villarreal-Martinez
- Hematology Service, Hospital Universitario 'Dr. José Eleuterio González', Universidad Autonoma de Nuevo Leon , Monterrey , Mexico
| | - Marisol Ibarra-Ramirez
- Departamento de Genetica, Facultad de Medicina, Universidad Autónoma de Nuevo Leon , Monterrey , Mexico
| | - Idalia Garza-Veloz
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico.,Program of Doctorate in Sciences with Orientation in Molecular Medicine, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico
| | - Edith Cardenas-Vargas
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico.,Program of Doctorate in Sciences with Orientation in Molecular Medicine, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico.,Hospital General Zacatecas 'Luz González Cosío' , Zacatecas , Mexico
| | - Ivan Marino-Martinez
- Departamento de Patologia, Facultad de Medicina, Universidad Autonoma de Nuevo Leon , Monterrey , Mexico
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico.,Program of Doctorate in Sciences with Orientation in Molecular Medicine, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University , Zacatecas , Mexico
| |
Collapse
|
22
|
Martin GH, Roy N, Chakraborty S, Desrichard A, Chung SS, Woolthuis CM, Hu W, Berezniuk I, Garrett-Bakelman FE, Hamann J, Devlin SM, Chan TA, Park CY. CD97 is a critical regulator of acute myeloid leukemia stem cell function. J Exp Med 2019; 216:2362-2377. [PMID: 31371381 PMCID: PMC6781010 DOI: 10.1084/jem.20190598] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 05/20/2019] [Accepted: 06/27/2019] [Indexed: 12/15/2022] Open
Abstract
Despite significant efforts to improve therapies for acute myeloid leukemia (AML), clinical outcomes remain poor. Understanding the mechanisms that regulate the development and maintenance of leukemic stem cells (LSCs) is important to reveal new therapeutic opportunities. We have identified CD97, a member of the adhesion class of G protein-coupled receptors (GPCRs), as a frequently up-regulated antigen on AML blasts that is a critical regulator of blast function. High levels of CD97 correlate with poor prognosis, and silencing of CD97 reduces disease aggressiveness in vivo. These phenotypes are due to CD97's ability to promote proliferation, survival, and the maintenance of the undifferentiated state in leukemic blasts. Collectively, our data credential CD97 as a promising therapeutic target on LSCs in AML.
Collapse
Affiliation(s)
- Gaëlle H Martin
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.,Department of Pathology, New York University School of Medicine, New York, NY
| | - Nainita Roy
- Department of Pathology, New York University School of Medicine, New York, NY
| | - Sohini Chakraborty
- Department of Pathology, New York University School of Medicine, New York, NY
| | - Alexis Desrichard
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Stephen S Chung
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.,Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Carolien M Woolthuis
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Wenhuo Hu
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Iryna Berezniuk
- Department of Pathology, New York University School of Medicine, New York, NY
| | - Francine E Garrett-Bakelman
- Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.,Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA.,Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York, NY
| | - Jörg Hamann
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Sean M Devlin
- Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Timothy A Chan
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.,Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
| | - Christopher Y Park
- Department of Pathology, New York University School of Medicine, New York, NY
| |
Collapse
|
23
|
Zhang Q, Hu H, Chen SY, Liu CJ, Hu FF, Yu J, Wu Y, Guo AY. Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL. GENOMICS PROTEOMICS & BIOINFORMATICS 2019; 17:190-200. [PMID: 31201998 PMCID: PMC6620363 DOI: 10.1016/j.gpb.2018.12.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Revised: 11/06/2018] [Accepted: 12/30/2018] [Indexed: 12/31/2022]
Abstract
Chimeric antigen receptor (CAR) T cell therapy has exhibited dramatic anti-tumor efficacy in clinical trials. In this study, we reported the transcriptome profiles of bone marrow cells in four B cell acute lymphoblastic leukemia (B-ALL) patients before and after CD19-specific CAR-T therapy. CD19-CAR-T therapy remarkably reduced the number of leukemia cells, and three patients achieved bone marrow remission (minimal residual disease negative). The efficacy of CD19-CAR-T therapy on B-ALL was positively correlated with the abundance of CAR and immune cell subpopulations, e.g., CD8+ T cells and natural killer (NK) cells, in the bone marrow. Additionally, CD19-CAR-T therapy mainly influenced the expression of genes linked to cell cycle and immune response pathways, including the NK cell mediated cytotoxicity and NOD-like receptor signaling pathways. The regulatory network analyses revealed that microRNAs (e.g., miR-148a-3p and miR-375), acting as oncogenes or tumor suppressors, could regulate the crosstalk between the genes encoding transcription factors (TFs; e.g., JUN and FOS) and histones (e.g., HIST1H4A and HIST2H4A) involved in CD19-CAR-T therapy. Furthermore, many long non-coding RNAs showed a high degree of co-expression with TFs or histones (e.g., FOS and HIST1H4B) and were associated with immune processes. These transcriptome analyses provided important clues for further understanding the gene expression and related mechanisms underlying the efficacy of CAR-T immunotherapy.
Collapse
Affiliation(s)
- Qiong Zhang
- Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Hui Hu
- Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Si-Yi Chen
- Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Chun-Jie Liu
- Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Fei-Fei Hu
- Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Jianming Yu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - Yaohui Wu
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
| | - An-Yuan Guo
- Hubei Bioinformatics and Molecular Imaging Key Laboratory, Department of Bioinformatics and Systems Biology, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
| |
Collapse
|
24
|
Katoh M, Katoh M. CD157 and CD200 at the crossroads of endothelial remodeling and immune regulation. Stem Cell Investig 2019; 6:10. [PMID: 31119148 DOI: 10.21037/sci.2019.04.01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2019] [Accepted: 04/08/2019] [Indexed: 01/04/2023]
Affiliation(s)
| | - Masaru Katoh
- Department of Omics Network, National Cancer Center, Tokyo, Japan
| |
Collapse
|
25
|
Kleo K, Dimitrova L, Oker E, Tomaszewski N, Berg E, Taruttis F, Engelmann JC, Schwarzfischer P, Reinders J, Spang R, Gronwald W, Oefner PJ, Hummel M. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma. BMC Cancer 2019; 19:322. [PMID: 30953469 PMCID: PMC6451309 DOI: 10.1186/s12885-019-5537-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Accepted: 03/27/2019] [Indexed: 12/27/2022] Open
Abstract
Background MYC is a heterogeneously expressed transcription factor that plays a multifunctional role in many biological processes such as cell proliferation and differentiation. It is also associated with many types of cancer including the malignant lymphomas. There are two types of aggressive B-cell lymphoma, namely Burkitt lymphoma (BL) and a subgroup of diffuse large cell lymphoma (DLBCL), which both carry MYC translocations and overexpress MYC but both differ significantly in their clinical outcome. In DLBCL, MYC translocations are associated with an aggressive behavior and poor outcome, whereas MYC-positive BL show a superior outcome. Methods To shed light on this phenomenon, we investigated the different modes of actions of MYC in aggressive B-cell lymphoma cell lines subdivided into three groups: (i) MYC-positive BL, (ii) DLBCL with MYC translocation (DLBCLpos) and (iii) DLBCL without MYC translocation (DLBCLneg) for control. In order to identify genome-wide MYC-DNA binding sites a chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-Seq) was performed. In addition, ChIP-Seq for H3K4me3 was used for determination of genomic regions accessible for transcriptional activity. These data were supplemented with gene expression data derived from RNA-Seq. Results Bioinformatics integration of all data sets revealed different MYC-binding patterns and transcriptional profiles in MYC-positive BL and DLBCL cell lines indicating different functional roles of MYC for gene regulation in aggressive B-cell lymphomas. Based on this multi-omics analysis we identified ADGRE5 (alias CD97) - a member of the EGF-TM7 subfamily of adhesion G protein-coupled receptors - as a MYC target gene, which is specifically expressed in BL but not in DLBCL regardless of MYC translocation. Conclusion Our study describes a diverse genome-wide MYC-DNA binding pattern in BL and DLBCL cell lines with and without MYC translocations. Furthermore, we identified ADREG5 as a MYC target gene able to discriminate between BL and DLBCL irrespectively of the presence of MYC breaks in DLBCL. Since ADGRE5 plays an important role in tumor cell formation, metastasis and invasion, it might also be instrumental to better understand the different pathobiology of BL and DLBCL and help to explain discrepant clinical characteristics of BL and DLBCL. Electronic supplementary material The online version of this article (10.1186/s12885-019-5537-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Karsten Kleo
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, D-10117, Berlin, Germany.
| | - Lora Dimitrova
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, D-10117, Berlin, Germany
| | - Elisabeth Oker
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, D-10117, Berlin, Germany
| | - Nancy Tomaszewski
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, D-10117, Berlin, Germany
| | - Erika Berg
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, D-10117, Berlin, Germany
| | - Franziska Taruttis
- Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, D-93053, Regensburg, Germany
| | - Julia C Engelmann
- Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, D-93053, Regensburg, Germany.,Present address: Department of Marine Microbiology and Biogeochemistry, NIOZ Royal Netherlands Institute for Sea Research, 1790, AB, Den Burg, The Netherlands
| | - Philipp Schwarzfischer
- Functional Genomics, Institute of Functional Genomics, University of Regensburg, D-93053, Regensburg, Germany
| | - Jörg Reinders
- Functional Genomics, Institute of Functional Genomics, University of Regensburg, D-93053, Regensburg, Germany
| | - Rainer Spang
- Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, D-93053, Regensburg, Germany
| | - Wolfram Gronwald
- Functional Genomics, Institute of Functional Genomics, University of Regensburg, D-93053, Regensburg, Germany
| | - Peter J Oefner
- Functional Genomics, Institute of Functional Genomics, University of Regensburg, D-93053, Regensburg, Germany
| | - Michael Hummel
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, D-10117, Berlin, Germany
| |
Collapse
|
26
|
Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res 2019; 79:2466-2479. [DOI: 10.1158/0008-5472.can-18-2970] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 02/08/2019] [Accepted: 03/29/2019] [Indexed: 11/16/2022]
|
27
|
Buldini B, Maurer-Granofszky M, Varotto E, Dworzak MN. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. Front Pediatr 2019; 7:412. [PMID: 31681710 PMCID: PMC6798174 DOI: 10.3389/fped.2019.00412] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Accepted: 09/25/2019] [Indexed: 01/10/2023] Open
Abstract
Minimal residual disease (MRD) by multiparametric flow cytometry (MFC) has been recently shown as a strong and independent prognostic marker of relapse in pediatric AML (pedAML) when measured at specific time points during Induction and/or Consolidation therapy. Hence, MFC-MRD has the potential to refine the current strategies of pedAML risk stratification, traditionally based on the cytogenetic and molecular genetic aberrations at diagnosis. Consequently, it may guide the modulation of therapy intensity and clinical decision making. However, the use of non-standardized protocols, including different staining panels, analysis, and gating strategies, may hamper a broad implementation of MFC-MRD monitoring in clinical routine. Besides, the thresholds of MRD positivity still need to be validated in large, prospective and multi-center clinical studies, as well as optimal time points of MRD assessment during therapy, to better discriminate patients with different prognosis. In the present review, we summarize the most relevant findings on MFC-MRD testing in pedAML. We examine the clinical significance of MFC-MRD and the recent advances in its standardization, including innovative approaches with an automated analysis of MFC-MRD data. We also touch upon other technologies for MRD assessment in AML, such as quantitative genomic breakpoint PCR, current challenges and future strategies to enable full incorporation of MFC-MRD into clinical practice.
Collapse
Affiliation(s)
- Barbara Buldini
- Laboratory of Hematology-Oncology, Department of Woman's and Child's Health, University of Padova, Padova, Italy
| | | | - Elena Varotto
- Laboratory of Hematology-Oncology, Department of Woman's and Child's Health, University of Padova, Padova, Italy
| | - Michael N Dworzak
- Children's Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Vienna, Austria
| |
Collapse
|
28
|
Singh M, Bhatia P, Shandilya JK, Rawat A, Varma N, Sachdeva MS, Trehan A, Bansal D, Jain R, Totadri S. Low Expression of Leucocyte Associated Immunoglobulin Like Receptor-1 (LAIR-1/CD305) in a Cohort of Pediatric Acute Lymphoblastic Leukemia Cases. Asian Pac J Cancer Prev 2018; 19:3131-3135. [PMID: 30486600 PMCID: PMC6318422 DOI: 10.31557/apjcp.2018.19.11.3131] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Background: Immunophenotypic markers can play significant role in prognostic assessment for different cancers and leukocyte-associated Ig-like receptor (LAIR-1) is a recently identified inhibitory immuno-receptor. Methods: We measured LAIR-1 expression in paediatric ALL patients (n-42) and appropriate controls by flow cytometry. Median fluorescence intensities (MFIs) were calculated and correlated with demographic and clinical variables and early treatment outcome parameters. Results: The ALL cohort had an age range of 1 - 11 y and a M:F ratio of 2.5:1. 64% had WBC counts <50 x 109/L and 15 (36%) >50 x 109/L, 52% being standard risk and 48% high risk. There were 6 cases of T-ALL and 36 of B-ALL. AML1-TEL, E2A-PBX, BCR-ABL and MLL-AF4 transcripts were noted in 3, 6, 2 and 1 patient, respectively. Day 8 ABC was <1,000 in 31 and >1,000 in 8 cases, while 30 had low and 7 high MRD (both >0.01) at day 35 of treatment. The median MFI for LAIR-1 expression in control cases was 8.2 (range 7.76-11.69) and in ALL cases 4.02 (range 0.56 to 11.87), with 74% (n-31) of ALL cases showing reduced LAIR-1 expression. However, no significant correlations were found between standard ALL risk factors and LAIR-1 expression. Out of 42 patients, 4 died during induction treatment and one exited therapy, 60% (n-3/5) of these featuring low expression of LAIR-1. Also ALL patients with low LAIR-1 expression had t (12;21), t (1;19) and t (4;11) translocations in 2, 4 and 1 samples, respectively, but none had t (9;22). Of those with high LAIR-1 expression, 2 had t (9;22) (MFIs-14.43 and 11.87). Conclusions: This pilot study of LAIR-1expression in ALL suggests low expression of the inhibitory molecule in leukemic cells. However, the findings need to be confirmed with larger cohort, along with studies focusing on pathophysiological roles in leukemic clone survival and escape from the immune system.
Collapse
Affiliation(s)
- Minu Singh
- Pediatric Haematology-Oncology Unit, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Bausch-Fluck D, Goldmann U, Müller S, van Oostrum M, Müller M, Schubert OT, Wollscheid B. The in silico human surfaceome. Proc Natl Acad Sci U S A 2018; 115:E10988-E10997. [PMID: 30373828 PMCID: PMC6243280 DOI: 10.1073/pnas.1808790115] [Citation(s) in RCA: 188] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Cell-surface proteins are of great biomedical importance, as demonstrated by the fact that 66% of approved human drugs listed in the DrugBank database target a cell-surface protein. Despite this biomedical relevance, there has been no comprehensive assessment of the human surfaceome, and only a fraction of the predicted 5,000 human transmembrane proteins have been shown to be located at the plasma membrane. To enable analysis of the human surfaceome, we developed the surfaceome predictor SURFY, based on machine learning. As a training set, we used experimentally verified high-confidence cell-surface proteins from the Cell Surface Protein Atlas (CSPA) and trained a random forest classifier on 131 features per protein and, specifically, per topological domain. SURFY was used to predict a human surfaceome of 2,886 proteins with an accuracy of 93.5%, which shows excellent overlap with known cell-surface protein classes (i.e., receptors). In deposited mRNA data, we found that between 543 and 1,100 surfaceome genes were expressed in cancer cell lines and maximally 1,700 surfaceome genes were expressed in embryonic stem cells and derivative lines. Thus, the surfaceome diversity depends on cell type and appears to be more dynamic than the nonsurface proteome. To make the predicted surfaceome readily accessible to the research community, we provide visualization tools for intuitive interrogation (wlab.ethz.ch/surfaceome). The in silico surfaceome enables the filtering of data generated by multiomics screens and supports the elucidation of the surfaceome nanoscale organization.
Collapse
Affiliation(s)
- Damaris Bausch-Fluck
- Institute of Molecular Systems Biology at the Department of Biology, ETH Zurich, 8093 Zurich, Switzerland
- Biomedical Proteomics Platform, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland
| | - Ulrich Goldmann
- Institute of Molecular Systems Biology at the Department of Biology, ETH Zurich, 8093 Zurich, Switzerland
| | - Sebastian Müller
- Institute of Molecular Systems Biology at the Department of Biology, ETH Zurich, 8093 Zurich, Switzerland
| | - Marc van Oostrum
- Institute of Molecular Systems Biology at the Department of Biology, ETH Zurich, 8093 Zurich, Switzerland
- Biomedical Proteomics Platform, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland
| | - Maik Müller
- Institute of Molecular Systems Biology at the Department of Biology, ETH Zurich, 8093 Zurich, Switzerland
- Biomedical Proteomics Platform, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland
| | - Olga T Schubert
- Institute of Molecular Systems Biology at the Department of Biology, ETH Zurich, 8093 Zurich, Switzerland
| | - Bernd Wollscheid
- Institute of Molecular Systems Biology at the Department of Biology, ETH Zurich, 8093 Zurich, Switzerland;
- Biomedical Proteomics Platform, Department of Health Sciences and Technology, ETH Zurich, 8093 Zurich, Switzerland
| |
Collapse
|
30
|
Ortolan E, Augeri S, Fissolo G, Musso I, Funaro A. CD157: From immunoregulatory protein to potential therapeutic target. Immunol Lett 2018; 205:59-64. [PMID: 29936181 DOI: 10.1016/j.imlet.2018.06.007] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Accepted: 06/20/2018] [Indexed: 11/29/2022]
Abstract
CD157/BST1 glycosylphosphatidylinositol-anchored glycoprotein is an evolutionary conserved dual-function receptor and β-NAD+-metabolizing ectoenzyme of the ADP-ribosyl cyclases gene family. Identified as bone marrow stromal cell and myeloid cell differentiation antigen, CD157 turned out to have a wider expression than originally assumed. The functional significance of human CD157 as an enzyme remains unclear, while it was well established in mouse models. Conversely, the receptor role of CD157 has been clearly delineated. In physiological conditions, CD157 is a key player in regulating leukocyte adhesion, migration and diapedesis. Underlying these functional roles is the ability of CD157 to bind with high affinity selected extracellular matrix components within their heparin-binding domains. CD157 binding to extracellular matrix promotes its interaction with β1 and β2-integrins and induces the organization of a multimolecular complex that is instrumental to the delivery of synergistic outside-in signals leading to optimal cell adhesion and migration, both in physiological and in pathological situations. CD157 also regulates cell adhesion and migration and is a marker of adverse prognosis in epithelial ovarian cancer and pleural mesothelioma. This review focuses on human CD157 expression and functions and provides an overview on its role in human pathology and its emerging potential as target for antibody-mediated immunotherapy.
Collapse
Affiliation(s)
- Erika Ortolan
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126 Torino, Italy
| | - Stefania Augeri
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126 Torino, Italy
| | - Giulia Fissolo
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126 Torino, Italy
| | - Irene Musso
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126 Torino, Italy
| | - Ada Funaro
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Via Santena 19, 10126 Torino, Italy.
| |
Collapse
|
31
|
Coustan-Smith E, Song G, Shurtleff S, Yeoh AEJ, Chng WJ, Chen SP, Rubnitz JE, Pui CH, Downing JR, Campana D. Universal monitoring of minimal residual disease in acute myeloid leukemia. JCI Insight 2018; 3:98561. [PMID: 29720577 DOI: 10.1172/jci.insight.98561] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2017] [Accepted: 03/28/2018] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND Optimal management of acute myeloid leukemia (AML) requires monitoring of treatment response, but minimal residual disease (MRD) may escape detection. We sought to identify distinctive features of AML cells for universal MRD monitoring. METHODS We compared genome-wide gene expression of AML cells from 157 patients with that of normal myeloblasts. Markers encoded by aberrantly expressed genes, including some previously associated with leukemia stem cells, were studied by flow cytometry in 240 patients with AML and in nonleukemic myeloblasts from 63 bone marrow samples. RESULTS Twenty-two (CD9, CD18, CD25, CD32, CD44, CD47, CD52, CD54, CD59, CD64, CD68, CD86, CD93, CD96, CD97, CD99, CD123, CD200, CD300a/c, CD366, CD371, and CX3CR1) markers were aberrantly expressed in AML. Leukemia-associated profiles defined by these markers extended to immature CD34+CD38- AML cells; expression remained stable during treatment. The markers yielded MRD measurements matching those of standard methods in 208 samples from 52 patients undergoing chemotherapy and revealed otherwise undetectable MRD. They allowed MRD monitoring in 129 consecutive patients, yielding prognostically significant results. Using a machine-learning algorithm to reduce high-dimensional data sets to 2-dimensional data, the markers allowed a clear visualization of MRD and could detect 1 leukemic cell among more than 100,000 normal cells. CONCLUSION The markers uncovered in this study allow universal and sensitive monitoring of MRD in AML. In combination with contemporary analytical tools, the markers improve the discrimination between leukemic and normal cells, thus facilitating data interpretation and, hence, the reliability of MRD results. FUNDING National Cancer Institute (CA60419 and CA21765); American Lebanese Syrian Associated Charities; National Medical Research Council of Singapore (1299/2011); Viva Foundation for Children with Cancer, Children's Cancer Foundation, Tote Board & Turf Club, and Lee Foundation of Singapore.
Collapse
Affiliation(s)
| | - Guangchun Song
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Sheila Shurtleff
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
| | - Allen Eng-Juh Yeoh
- Department of Pediatrics, National University of Singapore, Singapore.,National University Cancer Institute, Singapore, National University of Singapore, Singapore
| | - Wee Joo Chng
- National University Cancer Institute, Singapore, National University of Singapore, Singapore
| | - Siew Peng Chen
- Department of Pediatrics, National University of Singapore, Singapore
| | - Jeffrey E Rubnitz
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.,University of Tennessee Health Science Center, Memphis, Tennessee, USA
| | - Ching-Hon Pui
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.,Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.,University of Tennessee Health Science Center, Memphis, Tennessee, USA
| | - James R Downing
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.,University of Tennessee Health Science Center, Memphis, Tennessee, USA
| | - Dario Campana
- Department of Pediatrics, National University of Singapore, Singapore.,National University Cancer Institute, Singapore, National University of Singapore, Singapore
| |
Collapse
|
32
|
Sędek Ł, Theunissen P, Sobral da Costa E, van der Sluijs-Gelling A, Mejstrikova E, Gaipa G, Sonsala A, Twardoch M, Oliveira E, Novakova M, Buracchi C, van Dongen JJM, Orfao A, van der Velden VHJ, Szczepański T. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. J Immunol Methods 2018. [PMID: 29530508 DOI: 10.1016/j.jim.2018.03.005] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND Optimal discrimination between leukemic blasts and normal B-cell precursors (BCP) is critical for treatment monitoring in BCP acute lymphoblastic leukemia (ALL); thus identification of markers differentially expressed on normal BCP and leukemic blasts is required. METHODS Multicenter analysis of CD73, CD86 and CD304 expression levels was performed in 282 pediatric BCP-ALL patients vs. normal bone marrow BCP, using normalized median fluorescence intensity (nMFI) values. RESULTS CD73 was expressed at abnormally higher levels (vs. pooled normal BCP) at diagnosis in 71/108 BCP-ALL patients (66%), whereas CD304 and CD86 in 119/202 (59%) and 58/100 (58%) patients, respectively. Expression of CD304 was detected at similar percentages in common-ALL and pre-B-ALL, while found at significantly lower frequencies in pro-B-ALL. A significant association (p = 0.009) was found between CD304 expression and the presence of the ETV6-RUNX1 fusion gene. In contrast, CD304 showed an inverse association with MLL gene rearrangements (p = 0.01). The expression levels of CD73, CD86 and CD304 at day 15 after starting therapy (MRD15) were stable or higher than at diagnosis in 35/37 (95%), 40/56 (71%) and 19/41 (46%) cases investigated, respectively. This was also associated with an increased mean nMFI at MRD15 vs. diagnosis of +24 and +3 nMFI units for CD73 and CD86, respectively. In addition, gain of expression of CD73 and CD86 at MRD15 for cases that were originally negative for these markers at diagnosis was observed in 16% and 18% of cases, respectively. Of note, CD304 remained aberrantly positive in 63% of patients, despite its levels of expression decreased at follow-up in 54% of cases. CONCLUSIONS Here we show that CD73, CD86 and CD304 are aberrantly (over)expressed in a substantial percentage of BCP-ALL patients and that their expression profile remains relatively stable early after starting therapy, supporting their potential contribution to improved MRD analysis by flow cytometry.
Collapse
Affiliation(s)
- Łukasz Sędek
- Department of Microbiology and Immunology, Medical University of Silesia in Katowice (SUM), ul. Jordana 19, 41-808 Zabrze, Poland
| | - Prisca Theunissen
- Department of Immunology, Erasmus MC, University Medical Center Rotterdam (Erasmus MC), Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
| | - Elaine Sobral da Costa
- Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Av. Horacio Macedo, Predio do CT, CEP 21941-914 Rio de Janeiro, Brazil
| | - Alita van der Sluijs-Gelling
- Department of Immunohematology and Blood Transfusion (IHB), Leiden University Medical Center (LUMC), Albinusdreef 2, 2300 RC Leiden, The Netherlands
| | - Ester Mejstrikova
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University (CU), V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Giuseppe Gaipa
- Centro Ricerca Tettamanti, Clinica Pediatrica Università di Milano-Bicocca, Via Pergolesi 33, 20900 Monza, Italy
| | - Alicja Sonsala
- Department of Pediatric Hematology and Oncology, Medical University of Silesia in Katowice (SUM), ul. 3 Maja 13-15, 41-800 Zabrze, Poland
| | - Magdalena Twardoch
- Department of Pediatric Hematology and Oncology, Medical University of Silesia in Katowice (SUM), ul. 3 Maja 13-15, 41-800 Zabrze, Poland
| | - Elen Oliveira
- Pediatrics Institute IPPMG, Faculty of Medicine, Federal University of Rio de Janeiro, Av. Horacio Macedo, Predio do CT, CEP 21941-914 Rio de Janeiro, Brazil
| | - Michaela Novakova
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University (CU), V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Chiara Buracchi
- Centro Ricerca Tettamanti, Clinica Pediatrica Università di Milano-Bicocca, Via Pergolesi 33, 20900 Monza, Italy
| | - Jacques J M van Dongen
- Department of Immunohematology and Blood Transfusion (IHB), Leiden University Medical Center (LUMC), Albinusdreef 2, 2300 RC Leiden, The Netherlands
| | - Alberto Orfao
- Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service (Nucleus), University of Salamanca (USAL), 37007 Salamanca, Spain; CIBERONC and Institute of Biomedical Research of Salamanca (IBSAL), Paseo de la Universidad de Coimbra, s/n, Campus Miguel de Unamuno, 37007 Salamanca, Spain.
| | - Vincent H J van der Velden
- Department of Immunology, Erasmus MC, University Medical Center Rotterdam (Erasmus MC), Wytemaweg 80, 3015 CN Rotterdam, The Netherlands
| | - Tomasz Szczepański
- Department of Pediatric Hematology and Oncology, Medical University of Silesia in Katowice (SUM), ul. 3 Maja 13-15, 41-800 Zabrze, Poland
| | | |
Collapse
|
33
|
Haverland NA, Waas M, Ntai I, Keppel T, Gundry RL, Kelleher NL. Cell Surface Proteomics of N-Linked Glycoproteins for Typing of Human Lymphocytes. Proteomics 2018; 17. [PMID: 28834292 DOI: 10.1002/pmic.201700156] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 07/27/2017] [Indexed: 11/12/2022]
Abstract
Lymphocytes are immune cells that are critical for the maintenance of adaptive immunity. Differentiation of lymphoid progenitors yields B-, T-, and NK-cell subtypes that individually correlate with specific forms of leukemia or lymphoma. Therefore, it is imperative a precise method of cell categorization is utilized to detect differences in distinct disease states present in patients. One viable means of classification involves evaluation of the cell surface proteome of lymphoid malignancies. Specifically, this manuscript details the use of an antibody independent approach known as Cell Surface Capture Technology, to assess the N-glycoproteome of four human lymphocyte cell lines. Altogether, 404 cell surface N-glycoproteins were identified as markers for specific cell types involved in lymphocytic malignancies, including 82 N-glycoproteins that had not been previously been described for B or T cells within the Cell Surface Protein Atlas. Comparative analysis, hierarchical clustering techniques, and label-free quantitation were used to reveal proteins most informative for each cell type. Undoubtedly, the characterization of the cell surface proteome of lymphoid malignancies is a first step toward improving personalized diagnosis and treatment of leukemia and lymphoma.
Collapse
Affiliation(s)
- Nicole A Haverland
- Departments of Chemistry, Molecular Biosciences, and the Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA
| | - Matthew Waas
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Ioanna Ntai
- Departments of Chemistry, Molecular Biosciences, and the Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA
| | - Theodore Keppel
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Rebekah L Gundry
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Neil L Kelleher
- Departments of Chemistry, Molecular Biosciences, and the Proteomics Center of Excellence, Northwestern University, Evanston, IL, USA
| |
Collapse
|
34
|
Ferrero E, Lo Buono N, Morone S, Parrotta R, Mancini C, Brusco A, Giacomino A, Augeri S, Rosal-Vela A, García-Rodríguez S, Zubiaur M, Sancho J, Fiorio Pla A, Funaro A. Human canonical CD157/Bst1 is an alternatively spliced isoform masking a previously unidentified primate-specific exon included in a novel transcript. Sci Rep 2017; 7:15923. [PMID: 29162908 PMCID: PMC5698419 DOI: 10.1038/s41598-017-16184-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Accepted: 11/07/2017] [Indexed: 11/26/2022] Open
Abstract
CD157/Bst1 is a dual-function receptor and β-NAD+-metabolizing ectoenzyme of the ADP-ribosyl cyclase family. Expressed in human peripheral blood neutrophils and monocytes, CD157 interacts with extracellular matrix components and regulates leukocyte diapedesis via integrin-mediated signalling in inflammation. CD157 also regulates cell migration and is a marker of adverse prognosis in epithelial ovarian cancer and pleural mesothelioma. One form of CD157 is known to date: the canonical sequence of 318 aa from a 9-exon transcript encoded by BST1 on human chromosome 4. Here we describe a second BST1 transcript, consisting of 10 exons, in human neutrophils. This transcript includes an unreported exon, exon 1b, located between exons 1 and 2 of BST1. Inclusion of exon 1b in frame yields CD157-002, a novel proteoform of 333 aa: exclusion of exon 1b by alternative splicing generates canonical CD157, the dominant proteoform in neutrophils and other tissues analysed here. In comparative functional analyses, both proteoforms were indistinguishable in cell surface localization, specific mAb binding, and behaviour in cell adhesion and migration. However, NAD glycohydrolase activity was detected in canonical CD157 alone. Comparative phylogenetics indicate that exon 1b is a genomic innovation acquired during primate evolution, pointing to the importance of alternative splicing for CD157 function.
Collapse
Affiliation(s)
- Enza Ferrero
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy.
| | - Nicola Lo Buono
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy.,San Raffaele Diabetes Research Institute, San Raffaele Hospital, 20132, Milano, Italy
| | - Simona Morone
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy
| | - Rossella Parrotta
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy
| | - Cecilia Mancini
- Laboratory of Medical Genetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy
| | - Alfredo Brusco
- Laboratory of Medical Genetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy
| | - Alice Giacomino
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy
| | - Stefania Augeri
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy
| | - Antonio Rosal-Vela
- Department of Cellular Biology and Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Parque Tecnológico de la Salud de Granada, 18016, Granada, Spain
| | - Sonia García-Rodríguez
- Department of Cellular Biology and Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Parque Tecnológico de la Salud de Granada, 18016, Granada, Spain
| | - Mercedes Zubiaur
- Department of Cellular Biology and Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Parque Tecnológico de la Salud de Granada, 18016, Granada, Spain
| | - Jaime Sancho
- Department of Cellular Biology and Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Parque Tecnológico de la Salud de Granada, 18016, Granada, Spain
| | - Alessandra Fiorio Pla
- Department of Life Sciences and Systems Biology, University of Torino, 10123, Torino, Italy
| | - Ada Funaro
- Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126, Torino, Italy.
| |
Collapse
|
35
|
Bürgler S, Nadal D. Pediatric precursor B acute lymphoblastic leukemia: are T helper cells the missing link in the infectious etiology theory? Mol Cell Pediatr 2017; 4:6. [PMID: 28508352 PMCID: PMC5432458 DOI: 10.1186/s40348-017-0072-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 04/25/2017] [Indexed: 01/09/2023] Open
Abstract
Precursor B acute lymphoblastic leukemia (BCP-ALL), the most common childhood malignancy, arises from an expansion of malignant B cell precursors in the bone marrow. Epidemiological studies suggest that infections or immune responses to infections may promote such an expansion and thus BCP-ALL development. Nevertheless, a specific pathogen responsible for this process has not been identified. BCP-ALL cells critically depend on interactions with the bone marrow microenvironment. The bone marrow is also home to memory T helper (Th) cells that have previously expanded during an immune response in the periphery. In secondary lymphoid organs, Th cells can interact with malignant cells of mature B cell origin, while such interactions between Th cells and malignant immature B cell in the bone marrow have not been described yet. Nevertheless, literature supports a model where Th cells—expanded during an infection in early childhood—migrate to the bone marrow and support BCP-ALL cells as they support normal B cells. Further research is required to mechanistically confirm this model and to elucidate the interaction pathways between leukemia cells and cells of the tumor microenvironment. As benefit, targeting these interactions could be included in current treatment regimens to increase therapeutic efficiency and to reduce relapses.
Collapse
Affiliation(s)
- Simone Bürgler
- Experimental Infectious Diseases and Cancer Research, University Children's Hospital Zürich, 8008, Zürich, Switzerland.
| | - David Nadal
- Experimental Infectious Diseases and Cancer Research, University Children's Hospital Zürich, 8008, Zürich, Switzerland
| |
Collapse
|
36
|
Theunissen PMJ, Sedek L, De Haas V, Szczepanski T, Van Der Sluijs A, Mejstrikova E, Nováková M, Kalina T, Lecrevisse Q, Orfao A, Lankester AC, van Dongen JJM, Van Der Velden VHJ. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. Br J Haematol 2017; 178:257-266. [DOI: 10.1111/bjh.14682] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 01/18/2017] [Indexed: 01/23/2023]
Affiliation(s)
- Prisca M. J. Theunissen
- Department of Immunology; Erasmus MC, University Medical Centre Rotterdam; Rotterdam the Netherlands
| | - Lukasz Sedek
- Department of Paediatric Haematology and Oncology; Zabrze Poland
- Medical University of Silesia (SUM); Katowice Poland
| | | | - Tomasz Szczepanski
- Department of Paediatric Haematology and Oncology; Zabrze Poland
- Medical University of Silesia (SUM); Katowice Poland
| | | | - Ester Mejstrikova
- Department of Paediatric Haematology and Oncology; 2nd Faculty of Medicine; Charles University (DPH/O) and University Hospital Motol; Prague Czech Republic
| | - Michaela Nováková
- Department of Paediatric Haematology and Oncology; 2nd Faculty of Medicine; Charles University (DPH/O) and University Hospital Motol; Prague Czech Republic
| | - Tomas Kalina
- Department of Paediatric Haematology and Oncology; 2nd Faculty of Medicine; Charles University (DPH/O) and University Hospital Motol; Prague Czech Republic
| | - Quentin Lecrevisse
- Cancer Research Centre (IBMCC-CSIC); Department of Medicine and Cytometry Service; University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL); Salamanca Spain
| | - Alberto Orfao
- Cancer Research Centre (IBMCC-CSIC); Department of Medicine and Cytometry Service; University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL); Salamanca Spain
| | - Arjan C. Lankester
- Department of Paediatrics; Leiden University Medical Centre; Leiden the Netherlands
| | - Jacques J. M. van Dongen
- Department of Immunology; Erasmus MC, University Medical Centre Rotterdam; Rotterdam the Netherlands
- Department of Immunohaematology and Blood Transfusion; Leiden University Medical Centre; Leiden the Netherlands
| | | | | |
Collapse
|
37
|
McGinn OJ, Krishnan S, Bourquin JP, Sapra P, Dempsey C, Saha V, Stern PL. Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia. Haematologica 2017; 102:1075-1084. [PMID: 28341731 PMCID: PMC5451339 DOI: 10.3324/haematol.2016.158485] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 03/15/2017] [Indexed: 12/29/2022] Open
Abstract
Outcome in childhood acute lymphoblastic leukemia is prognosticated from levels of minimal residual disease after remission induction therapy. Higher levels of minimal residual disease are associated with inferior results even with intensification of therapy, thus suggesting that identification and targeting of minimal residual disease cells could be a therapeutic strategy. Here we identify high expression of 5T4 in subclonal populations of patient-derived xenografts from patients with high, post-induction levels of minimal residual disease. 5T4-positive cells showed preferential ability to overcome the NOD-scidIL2Rγnull mouse xenograft barrier, migrated in vitro on a CXCL12 gradient, preferentially localized to bone marrow in vivo and displayed the ability to reconstitute the original clonal composition on limited dilution engraftment. Treatment with A1mcMMAF (a 5T4-antibody drug conjugate) significantly improved survival without overt toxicity in mice engrafted with a 5T4-positive acute lymphoblastic leukemia cell line. Mice engrafted with 5T4-positive patient-derived xenograft cells were treated with combination chemotherapy or dexamethasone alone and then given A1mcMMAF in the minimal residual disease setting. Combination chemotherapy was toxic to NOD-scidIL2Rγnull mice. While dexamethasone or A1mcMMAF alone improved outcomes, the sequential administration of dexamethasone and A1mcMMAF significantly improved survival (P=0.0006) over either monotherapy. These data show that specifically targeting minimal residual disease cells improved outcomes and support further investigation of A1mcMMAF in patients with high-risk B-cell precursor acute lymphoblastic leukemia identified by 5T4 expression at diagnosis.
Collapse
Affiliation(s)
- Owen J McGinn
- Immunology, Division of Molecular & Clinical Cancer Sciences, University of Manchester, UK
| | - Shekhar Krishnan
- Paediatric Oncology, Division of Molecular & Clinical Cancer Sciences, University of Manchester, UK.,Tata Translational Cancer Research Center, Tata Medical Center, Kolkata, India
| | - Jean-Pierre Bourquin
- Division of Oncology & Children's Research Center, University Children's Hospital, University of Zurich, Switzerland
| | - Puja Sapra
- Pfizer Inc. Pearl River, NY10965-1299, USA
| | - Clare Dempsey
- Paediatric Oncology, Division of Molecular & Clinical Cancer Sciences, University of Manchester, UK
| | - Vaskar Saha
- Paediatric Oncology, Division of Molecular & Clinical Cancer Sciences, University of Manchester, UK .,Tata Translational Cancer Research Center, Tata Medical Center, Kolkata, India
| | - Peter L Stern
- Immunology, Division of Molecular & Clinical Cancer Sciences, University of Manchester, UK
| |
Collapse
|
38
|
Glisovic-Aplenc T, Gill S, Spruce LA, Smith IR, Fazelinia H, Shestova O, Ding H, Tasian SK, Aplenc R, Seeholzer SH. Improved surfaceome coverage with a label-free nonaffinity-purified workflow. Proteomics 2017; 17. [PMID: 28116781 DOI: 10.1002/pmic.201600344] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Revised: 01/05/2017] [Accepted: 01/19/2017] [Indexed: 01/17/2023]
Abstract
The proteins of the cellular plasma membrane (PM) perform important functions relating to homeostasis and intercellular communication. Due to its overall low cellular abundance, amphipathic character, and low membrane-to-cytoplasm ratio, the PM proteome has been challenging to isolate and characterize, and is poorly represented in standard LC-MS/MS analyses. In this study, we employ sucrose gradient ultracentrifugation for the enrichment of the PM proteome, without chemical labeling and affinity purification, together with GeLCMS and use subsequent bioinformatics tools to select proteins associated with the PM/cell surface, herein referred to as the surfaceome. Using this methodology, we identify over 1900 cell surface associated proteins in a human acute myeloid leukemia cell line. These surface proteins comprise almost 50% of all detected cellular proteins, a number that substantially exceeds the depth of coverage in previously published studies describing the leukemia surfaceome.
Collapse
Affiliation(s)
- Tina Glisovic-Aplenc
- Division of Oncology, Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Saar Gill
- Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Lynn A Spruce
- Protein and Proteomics Core Facility, The Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA
| | - Ian R Smith
- Protein and Proteomics Core Facility, The Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA
| | - Hossein Fazelinia
- Protein and Proteomics Core Facility, The Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA
| | - Olga Shestova
- Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Hua Ding
- Protein and Proteomics Core Facility, The Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA
| | - Sarah K Tasian
- Division of Oncology, Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Richard Aplenc
- Division of Oncology, Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.,Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
| | - Steven H Seeholzer
- Protein and Proteomics Core Facility, The Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, USA
| |
Collapse
|
39
|
Langó T, Róna G, Hunyadi-Gulyás É, Turiák L, Varga J, Dobson L, Várady G, Drahos L, Vértessy BG, Medzihradszky KF, Szakács G, Tusnády GE. Identification of Extracellular Segments by Mass Spectrometry Improves Topology Prediction of Transmembrane Proteins. Sci Rep 2017; 7:42610. [PMID: 28211907 PMCID: PMC5304180 DOI: 10.1038/srep42610] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 01/11/2017] [Indexed: 01/17/2023] Open
Abstract
Transmembrane proteins play crucial role in signaling, ion transport, nutrient uptake, as well as in maintaining the dynamic equilibrium between the internal and external environment of cells. Despite their important biological functions and abundance, less than 2% of all determined structures are transmembrane proteins. Given the persisting technical difficulties associated with high resolution structure determination of transmembrane proteins, additional methods, including computational and experimental techniques remain vital in promoting our understanding of their topologies, 3D structures, functions and interactions. Here we report a method for the high-throughput determination of extracellular segments of transmembrane proteins based on the identification of surface labeled and biotin captured peptide fragments by LC/MS/MS. We show that reliable identification of extracellular protein segments increases the accuracy and reliability of existing topology prediction algorithms. Using the experimental topology data as constraints, our improved prediction tool provides accurate and reliable topology models for hundreds of human transmembrane proteins.
Collapse
Affiliation(s)
- Tamás Langó
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| | - Gergely Róna
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary.,Department of Applied Biotechnology and Food Sciences, Budapest University of Technology and Economics, Szent Gellért tér 4, Budapest, H-1111, Hungary.,Department of Biochemistry and Molecular Pharmacology, Perlmutter NYU Cancer Center, New York University School of Medicine, 522 First Avenue, SRB 1107, New York, NY 10016, USA
| | - Éva Hunyadi-Gulyás
- Laboratory of Proteomics Research, Biological Research Center of the Hungarian Academy of Sciences, Temesvari krt. 62, Szeged, H-6726, Hungary
| | - Lilla Turiák
- Institute of Organic Chemistry, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| | - Julia Varga
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| | - László Dobson
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| | - György Várady
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| | - László Drahos
- Institute of Organic Chemistry, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| | - Beáta G Vértessy
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary.,Department of Applied Biotechnology and Food Sciences, Budapest University of Technology and Economics, Szent Gellért tér 4, Budapest, H-1111, Hungary
| | - Katalin F Medzihradszky
- Laboratory of Proteomics Research, Biological Research Center of the Hungarian Academy of Sciences, Temesvari krt. 62, Szeged, H-6726, Hungary
| | - Gergely Szakács
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| | - Gábor E Tusnády
- Institute of Enzymology, RCNS, Hungarian Academy of Sciences, Magyar Tudósok krt 2, Budapest, H-1117 Hungary
| |
Collapse
|
40
|
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 2017; 129:e26-e37. [PMID: 28122742 DOI: 10.1182/blood-2016-09-738070] [Citation(s) in RCA: 160] [Impact Index Per Article: 22.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2016] [Accepted: 01/10/2017] [Indexed: 12/14/2022] Open
Abstract
Drug sensitivity and resistance testing on diagnostic leukemia samples should provide important functional information to guide actionable target and biomarker discovery. We provide proof of concept data by profiling 60 drugs on 68 acute lymphoblastic leukemia (ALL) samples mostly from resistant disease in cocultures of bone marrow stromal cells. Patient-derived xenografts retained the original pattern of mutations found in the matched patient material. Stromal coculture did not prevent leukemia cell cycle activity, but a specific sensitivity profile to cell cycle-related drugs identified samples with higher cell proliferation both in vitro and in vivo as leukemia xenografts. In patients with refractory relapses, individual patterns of marked drug resistance and exceptional responses to new agents of immediate clinical relevance were detected. The BCL2-inhibitor venetoclax was highly active below 10 nM in B-cell precursor ALL (BCP-ALL) subsets, including MLL-AF4 and TCF3-HLF ALL, and in some T-cell ALLs (T-ALLs), predicting in vivo activity as a single agent and in combination with dexamethasone and vincristine. Unexpected sensitivity to dasatinib with half maximal inhibitory concentration values below 20 nM was detected in 2 independent T-ALL cohorts, which correlated with similar cytotoxic activity of the SRC inhibitor KX2-391 and inhibition of SRC phosphorylation. A patient with refractory T-ALL was treated with dasatinib on the basis of drug profiling information and achieved a 5-month remission. Thus, drug profiling captures disease-relevant features and unexpected sensitivity to relevant drugs, which warrants further exploration of this functional assay in the context of clinical trials to develop drug repurposing strategies for patients with urgent medical needs.
Collapse
|
41
|
Wobus M, Bornhäuser M, Jacobi A, Kräter M, Otto O, Ortlepp C, Guck J, Ehninger G, Thiede C, Oelschlägel U. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. Oncotarget 2016; 6:38804-15. [PMID: 26462154 PMCID: PMC4770738 DOI: 10.18632/oncotarget.5661] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Accepted: 09/25/2015] [Indexed: 12/31/2022] Open
Abstract
Internal tandem duplications within the juxtamembrane region of the FMS-like tyrosine kinase receptor FLT3 (FLT3-ITD) represents one of the most common mutations in patients with acute myeloid leukemia (AML) which results in constitutive aberrant activation, increased proliferation of leukemic progenitors and is associated with an aggressive clinical phenotype. The expression of CD97, an EGF-TM7 receptor, has been linked to invasive behavior in thyroid and colorectal cancer. Here, we have investigated the association of CD97 with FLT3-ITD and its functional consequences in AML.Higher CD97 expression levels have been detected in 208 out of 385 primary AML samples. This was accompanied by a significantly increased bone marrow blast count as well as by mutations in the FLT3 gene. FLT3-ITD expressing cell lines as MV4-11 and MOLM-13 revealed significantly higher CD97 levels than FLT3 wildtype EOL-1, OCI-AML3 and HL-60 cells which were clearly decreased by the tyrosine kinase inhibitors PKC412 and SU5614. CD97 knock down by short hairpin RNA in MV4-11 cells resulted in inhibited trans-well migration towards fetal calf serum (FCS) and lysophosphatidic acid (LPA) being at least in part Rho-A dependent. Moreover, knock down of CD97 led to an altered mechanical phenotype, reduced adhesion to a stromal layer and lower wildtype FLT3 expression.Our results, thus, constitute the first evidence for the functional relevance of CD97 expression in FLT3-ITD AML cells rendering it a potential new theragnostic target.
Collapse
Affiliation(s)
- Manja Wobus
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany
| | - Martin Bornhäuser
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany.,German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany
| | - Angela Jacobi
- Biotechnology Center, Technische Universität Dresden, Dresden, Germany
| | - Martin Kräter
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany
| | - Oliver Otto
- Biotechnology Center, Technische Universität Dresden, Dresden, Germany
| | - Claudia Ortlepp
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany
| | - Jochen Guck
- Biotechnology Center, Technische Universität Dresden, Dresden, Germany
| | - Gerhard Ehninger
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany
| | - Christian Thiede
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany
| | - Uta Oelschlägel
- Division of Hematology, Oncology and Stem Cell Transplantation, Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany
| |
Collapse
|
42
|
Vit O, Man P, Kadek A, Hausner J, Sklenar J, Harant K, Novak P, Scigelova M, Woffendin G, Petrak J. Large-scale identification of membrane proteins based on analysis of trypsin-protected transmembrane segments. J Proteomics 2016; 149:15-22. [DOI: 10.1016/j.jprot.2016.03.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Revised: 02/03/2016] [Accepted: 03/04/2016] [Indexed: 01/06/2023]
|
43
|
Boheler KR, Gundry RL. Concise Review: Cell Surface N-Linked Glycoproteins as Potential Stem Cell Markers and Drug Targets. Stem Cells Transl Med 2016; 6:131-138. [PMID: 28170199 PMCID: PMC5442750 DOI: 10.5966/sctm.2016-0109] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Accepted: 06/13/2016] [Indexed: 12/28/2022] Open
Abstract
Stem cells and their derivatives hold great promise to advance regenerative medicine. Critical to the progression of this field is the identification and utilization of antibody‐accessible cell‐surface proteins for immunophenotyping and cell sorting—techniques essential for assessment and isolation of defined cell populations with known functional and therapeutic properties. Beyond their utility for cell identification and selection, cell‐surface proteins are also major targets for pharmacological intervention. Although comprehensive cell‐surface protein maps are highly valuable, they have been difficult to define until recently. In this review, we discuss the application of a contemporary targeted chemoproteomic‐based technique for defining the cell‐surface proteomes of stem and progenitor cells. In applying this approach to pluripotent stem cells (PSCs), these studies have improved the biological understanding of these cells, led to the enhanced use and development of antibodies suitable for immunophenotyping and sorting, and contributed to the repurposing of existing drugs without the need for high‐throughput screening. The utility of this latter approach was first demonstrated with human PSCs (hPSCs) through the identification of small molecules that are selectively toxic to hPSCs and have the potential for eliminating confounding and tumorigenic cells in hPSC‐derived progeny destined for research and transplantation. Overall, the cutting‐edge technologies reviewed here will accelerate the development of novel cell‐surface protein targets for immunophenotyping, new reagents to improve the isolation of therapeutically qualified cells, and pharmacological studies to advance the treatment of intractable diseases amenable to cell‐replacement therapies. Stem Cells Translational Medicine2017;6:131–138
Collapse
Affiliation(s)
- Kenneth R. Boheler
- Stem Cell and Regenerative Medicine Consortium, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China
| | - Rebekah L. Gundry
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
| |
Collapse
|
44
|
Renella R. Clinically-oriented proteomic investigation of sickle cell disease: Opportunities and challenges. Proteomics Clin Appl 2016; 10:816-30. [DOI: 10.1002/prca.201500133] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 04/05/2016] [Accepted: 05/02/2016] [Indexed: 12/29/2022]
Affiliation(s)
- Raffaele Renella
- Department of Pediatrics; Centre Hospitalier Universitaire Vaudois; Lausanne Switzerland
| |
Collapse
|
45
|
Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics 2016; 15:1246-61. [PMID: 26785729 DOI: 10.1074/mcp.m115.054593] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Indexed: 11/06/2022] Open
Abstract
Acute leukemia is a disease pathologically manifested at both genomic and proteomic levels. Molecular genetic technologies are currently widely used in clinical research. In contrast, sensitive and high-throughput proteomic techniques for performing protein analyses in patient samples are still lacking. Here, we used a technology based on size exclusion chromatography followed by immunoprecipitation of target proteins with an antibody bead array (Size Exclusion Chromatography-Microsphere-based Affinity Proteomics, SEC-MAP) to detect hundreds of proteins from a single sample. In addition, we developed semi-automatic bioinformatics tools to adapt this technology for high-content proteomic screening of pediatric acute leukemia patients.To confirm the utility of SEC-MAP in leukemia immunophenotyping, we tested 31 leukemia diagnostic markers in parallel by SEC-MAP and flow cytometry. We identified 28 antibodies suitable for both techniques. Eighteen of them provided excellent quantitative correlation between SEC-MAP and flow cytometry (p< 0.05). Next, SEC-MAP was applied to examine 57 diagnostic samples from patients with acute leukemia. In this assay, we used 632 different antibodies and detected 501 targets. Of those, 47 targets were differentially expressed between at least two of the three acute leukemia subgroups. The CD markers correlated with immunophenotypic categories as expected. From non-CD markers, we found DBN1, PAX5, or PTK2 overexpressed in B-cell precursor acute lymphoblastic leukemias, LAT, SH2D1A, or STAT5A overexpressed in T-cell acute lymphoblastic leukemias, and HCK, GLUD1, or SYK overexpressed in acute myeloid leukemias. In addition, OPAL1 overexpression corresponded to ETV6-RUNX1 chromosomal translocation.In summary, we demonstrated that SEC-MAP technology is a powerful tool for detecting hundreds of proteins in clinical samples obtained from pediatric acute leukemia patients. It provides information about protein size and reveals differences in protein expression between particular leukemia subgroups. Forty-seven of SEC-MAP identified targets were validated by other conventional method in this study.
Collapse
Affiliation(s)
- Veronika Kanderova
- From the ‡CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2 Faculty of Medicine, Charles University in Prague, V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Daniela Kuzilkova
- From the ‡CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2 Faculty of Medicine, Charles University in Prague, V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Jan Stuchly
- From the ‡CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2 Faculty of Medicine, Charles University in Prague, V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Martina Vaskova
- From the ‡CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2 Faculty of Medicine, Charles University in Prague, V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Tomas Brdicka
- §Institute of Molecular Genetics, Academy of Sciences of the Czech Republic; Videnska 1083, 14220 Prague, Czech Republic
| | - Karel Fiser
- From the ‡CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2 Faculty of Medicine, Charles University in Prague, V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Ondrej Hrusak
- From the ‡CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2 Faculty of Medicine, Charles University in Prague, V Uvalu 84, 15006 Prague 5, Czech Republic
| | - Fridtjof Lund-Johansen
- ¶Department of Immunology, Oslo University Hospital, Rikshospitalet; Sognsvannsveien 20, 0372 Oslo, Norway
| | - Tomas Kalina
- From the ‡CLIP - Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2 Faculty of Medicine, Charles University in Prague, V Uvalu 84, 15006 Prague 5, Czech Republic;
| |
Collapse
|
46
|
Abstract
Alterations in the homeostasis of several adhesion GPCRs (aGPCRs) have been observed in cancer. The main cellular functions regulated by aGPCRs are cell adhesion, migration, polarity, and guidance, which are all highly relevant to tumor cell biology. Expression of aGPCRs can be induced, increased, decreased, or silenced in the tumor or in stromal cells of the tumor microenvironment, including fibroblasts and endothelial and/or immune cells. For example, ADGRE5 (CD97) and ADGRG1 (GPR56) show increased expression in many cancers, and initial functional studies suggest that both are relevant for tumor cell migration and invasion. aGPCRs can also impact the regulation of angiogenesis by releasing soluble fragments following the cleavage of their extracellular domain (ECD) at the conserved GPCR-proteolytic site (GPS) or other more distal cleavage sites as typical for the ADGRB (BAI) family. Interrogation of in silico cancer databases suggests alterations in other aGPCR members and provides the impetus for further exploration of their potential role in cancer. Integration of knowledge on the expression, regulation, and function of aGPCRs in tumorigenesis is currently spurring the first preclinical studies to examine the potential of aGPCR or the related pathways as therapeutic targets.
Collapse
Affiliation(s)
- Gabriela Aust
- Department of Surgery, Research Laboratories, University of Leipzig, Liebigstraße 19, Leipzig, 04103, Germany.
| | - Dan Zhu
- Department of Neurosurgery and Hematology & Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA
| | - Erwin G Van Meir
- Department of Neurosurgery and Hematology & Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA
| | - Lei Xu
- Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY, 14642, USA
| |
Collapse
|
47
|
Hamann J, Aust G, Araç D, Engel FB, Formstone C, Fredriksson R, Hall RA, Harty BL, Kirchhoff C, Knapp B, Krishnan A, Liebscher I, Lin HH, Martinelli DC, Monk KR, Peeters MC, Piao X, Prömel S, Schöneberg T, Schwartz TW, Singer K, Stacey M, Ushkaryov YA, Vallon M, Wolfrum U, Wright MW, Xu L, Langenhan T, Schiöth HB. International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. Pharmacol Rev 2015; 67:338-67. [PMID: 25713288 DOI: 10.1124/pr.114.009647] [Citation(s) in RCA: 328] [Impact Index Per Article: 36.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The Adhesion family forms a large branch of the pharmacologically important superfamily of G protein-coupled receptors (GPCRs). As Adhesion GPCRs increasingly receive attention from a wide spectrum of biomedical fields, the Adhesion GPCR Consortium, together with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification, proposes a unified nomenclature for Adhesion GPCRs. The new names have ADGR as common dominator followed by a letter and a number to denote each subfamily and subtype, respectively. The new names, with old and alternative names within parentheses, are: ADGRA1 (GPR123), ADGRA2 (GPR124), ADGRA3 (GPR125), ADGRB1 (BAI1), ADGRB2 (BAI2), ADGRB3 (BAI3), ADGRC1 (CELSR1), ADGRC2 (CELSR2), ADGRC3 (CELSR3), ADGRD1 (GPR133), ADGRD2 (GPR144), ADGRE1 (EMR1, F4/80), ADGRE2 (EMR2), ADGRE3 (EMR3), ADGRE4 (EMR4), ADGRE5 (CD97), ADGRF1 (GPR110), ADGRF2 (GPR111), ADGRF3 (GPR113), ADGRF4 (GPR115), ADGRF5 (GPR116, Ig-Hepta), ADGRG1 (GPR56), ADGRG2 (GPR64, HE6), ADGRG3 (GPR97), ADGRG4 (GPR112), ADGRG5 (GPR114), ADGRG6 (GPR126), ADGRG7 (GPR128), ADGRL1 (latrophilin-1, CIRL-1, CL1), ADGRL2 (latrophilin-2, CIRL-2, CL2), ADGRL3 (latrophilin-3, CIRL-3, CL3), ADGRL4 (ELTD1, ETL), and ADGRV1 (VLGR1, GPR98). This review covers all major biologic aspects of Adhesion GPCRs, including evolutionary origins, interaction partners, signaling, expression, physiologic functions, and therapeutic potential.
Collapse
Affiliation(s)
- Jörg Hamann
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Gabriela Aust
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Demet Araç
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Felix B Engel
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Caroline Formstone
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Robert Fredriksson
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Randy A Hall
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Breanne L Harty
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Christiane Kirchhoff
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Barbara Knapp
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Arunkumar Krishnan
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Ines Liebscher
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Hsi-Hsien Lin
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - David C Martinelli
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Kelly R Monk
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Miriam C Peeters
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Xianhua Piao
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Simone Prömel
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Torsten Schöneberg
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Thue W Schwartz
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Kathleen Singer
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Martin Stacey
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Yuri A Ushkaryov
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Mario Vallon
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Uwe Wolfrum
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Mathew W Wright
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Lei Xu
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Tobias Langenhan
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| | - Helgi B Schiöth
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Surgery, Research Laboratories (G.A), and Institute of Biochemistry (I.L., S.P., T.S.), Medical Faculty, University of Leipzig, Leipzig, Germany; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, Illinois (D.A.); Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany (F.B.E.); MRC Centre for Developmental Neurobiology, King's College London, London, United Kingdom (C.F.); Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden (R.F., A.K., H.B.S.); Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia (R.A.H.); Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri (B.L.H., K.R.M.); Department for Andrology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (C.K.); Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University Mainz, Mainz, Germany (B.K., U.W.); Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan (H.-H.L.); Department of Molecular and Cellular Physiology (D.C.M.) and Division of Hematology (M.V.), Stanford University School of Medicine, Stanford, California; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands (M.C.P.); Department of Neuroscience and Pharmacology and Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark (M.C.P., T.W.S.); Division of Newborn Medicine, Department of Medicine, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts (X.P., K.S.); Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom (M.S.); Medway School of Pharmacy, University of Kent, Chatham, United Kingdom (Y.A.U.); HUGO Gene Nomen
| |
Collapse
|
48
|
Boutter J, Huang Y, Marovca B, Vonderheit A, Grotzer MA, Eckert C, Cario G, Wollscheid B, Horvath P, Bornhauser BC, Bourquin JP. Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget 2015; 5:11501-12. [PMID: 25415224 PMCID: PMC4294362 DOI: 10.18632/oncotarget.2572] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Accepted: 10/03/2014] [Indexed: 01/22/2023] Open
Abstract
Interactions with the bone marrow microenvironment are essential for leukemia survival and disease progression. We developed an imaging-based RNAi platform to identify protective cues from bone marrow derived mesenchymal stromal cells (MSC) that promote survival of primary acute lymphoblastic leukemia (ALL) cells. Using a candidate gene approach, we detected distinct responses of individual ALL cases to RNA interference with stromal targets. The strongest effects were observed when interfering with solute carrier family 3 member 2 (SLC3A2) expression, which forms the cystine transporter xc− when associated with SLC7A11. Import of cystine and metabolism to cysteine by stromal cells provides the limiting substrate to generate and maintain glutathione in ALL. This metabolic interaction reduces oxidative stress in ALL cells that depend on stromal xc−. Indeed, cysteine depletion using cysteine dioxygenase resulted in leukemia cell death. Thus, functional evaluation of intercellular interactions between leukemia cells and their microenvironment identifies a selective dependency of ALL cells on stromal metabolism for a relevant subgroup of cases, providing new opportunities to develop more personalized approaches to leukemia treatment.
Collapse
Affiliation(s)
- Jeannette Boutter
- Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland. Children's Research Center (CRC), University Children's Hospital Zurich, Zurich, Switzerland
| | - Yun Huang
- Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland. Children's Research Center (CRC), University Children's Hospital Zurich, Zurich, Switzerland
| | - Blerim Marovca
- Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland. Children's Research Center (CRC), University Children's Hospital Zurich, Zurich, Switzerland
| | | | - Michael A Grotzer
- Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland. Children's Research Center (CRC), University Children's Hospital Zurich, Zurich, Switzerland
| | - Cornelia Eckert
- Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Germany
| | - Gunnar Cario
- Department of Pediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany
| | - Bernd Wollscheid
- Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland
| | - Peter Horvath
- Synthetic and Systems Biology Unit, Biological Research Center, Szeged, Hungary. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Beat C Bornhauser
- Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland. Children's Research Center (CRC), University Children's Hospital Zurich, Zurich, Switzerland
| | - Jean-Pierre Bourquin
- Department of Pediatric Oncology, University Children's Hospital Zurich, Zurich, Switzerland. Children's Research Center (CRC), University Children's Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
49
|
Hsiao CC, Keysselt K, Chen HY, Sittig D, Hamann J, Lin HH, Aust G. The Adhesion GPCR CD97/ADGRE5 inhibits apoptosis. Int J Biochem Cell Biol 2015; 65:197-208. [PMID: 26071181 DOI: 10.1016/j.biocel.2015.06.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 05/29/2015] [Accepted: 06/08/2015] [Indexed: 10/23/2022]
Abstract
The Adhesion G protein-coupled receptor (GPCR) CD97/ADGRE5 is induced, upregulated, and/or biochemically modified in various malignancies, compared to the corresponding normal tissues. As tumor cells are generally more resistant to apoptosis, we here studied the ability of CD97 to regulate tumor cell survival under apoptotic conditions. Stable overexpression of wild-type CD97 reduced serum starvation- and staurosporine-induced intrinsic and tumor necrosis factor (TNF)/cycloheximide-induced extrinsic apoptosis, indicated by an increase in cell viability, a lower percentage of cells within the subG0/G1 phase, expressing annexin V, or having condensed nuclei, and a reduction of DNA laddering. Protection from cell death by CD97 was accompanied by an inhibition of caspase activation and modulation of anti- and pro-apoptotic members of the BCL-2 superfamily. shRNA-mediated knockdown of CD97 and, in part, truncation of the seven-span transmembrane (TM7) region of CD97 increased caspase-mediated apoptosis. Protection from apoptosis required not only the TM7 region but also cleavage of the receptor at its GPCR proteolysis site (GPS), whereas alternative splicing of its extracellular domain had no effect. Together, our data indicate a role of CD97 in tumor cell survival.
Collapse
Affiliation(s)
- Cheng-Chih Hsiao
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
| | - Kerstin Keysselt
- Department of Surgery, Research Laboratories, University of Leipzig, Leipzig, Germany
| | - Hsin-Yi Chen
- Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
| | - Doreen Sittig
- Department of Surgery, Research Laboratories, University of Leipzig, Leipzig, Germany
| | - Jörg Hamann
- Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Hsi-Hsien Lin
- Department of Microbiology and Immunology, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan; Chang Gung Immunology Consortium, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan.
| | - Gabriela Aust
- Department of Surgery, Research Laboratories, University of Leipzig, Leipzig, Germany.
| |
Collapse
|
50
|
Graessel A, Hauck SM, von Toerne C, Kloppmann E, Goldberg T, Koppensteiner H, Schindler M, Knapp B, Krause L, Dietz K, Schmidt-Weber CB, Suttner K. A Combined Omics Approach to Generate the Surface Atlas of Human Naive CD4+ T Cells during Early T-Cell Receptor Activation. Mol Cell Proteomics 2015; 14:2085-102. [PMID: 25991687 DOI: 10.1074/mcp.m114.045690] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Indexed: 12/24/2022] Open
Abstract
Naive CD4(+) T cells are the common precursors of multiple effector and memory T-cell subsets and possess a high plasticity in terms of differentiation potential. This stem-cell-like character is important for cell therapies aiming at regeneration of specific immunity. Cell surface proteins are crucial for recognition and response to signals mediated by other cells or environmental changes. Knowledge of cell surface proteins of human naive CD4(+) T cells and their changes during the early phase of T-cell activation is urgently needed for a guided differentiation of naive T cells and may support the selection of pluripotent cells for cell therapy. Periodate oxidation and aniline-catalyzed oxime ligation technology was applied with subsequent quantitative liquid chromatography-tandem MS to generate a data set describing the surface proteome of primary human naive CD4(+) T cells and to monitor dynamic changes during the early phase of activation. This led to the identification of 173 N-glycosylated surface proteins. To independently confirm the proteomic data set and to analyze the cell surface by an alternative technique a systematic phenotypic expression analysis of surface antigens via flow cytometry was performed. This screening expanded the previous data set, resulting in 229 surface proteins, which were expressed on naive unstimulated and activated CD4(+) T cells. Furthermore, we generated a surface expression atlas based on transcriptome data, experimental annotation, and predicted subcellular localization, and correlated the proteomics result with this transcriptional data set. This extensive surface atlas provides an overall naive CD4(+) T cell surface resource and will enable future studies aiming at a deeper understanding of mechanisms of T-cell biology allowing the identification of novel immune targets usable for the development of therapeutic treatments.
Collapse
Affiliation(s)
- Anke Graessel
- From the ‡Center of Allergy and Environment (ZAUM), Technische Universität und Helmholtz Zentrum München, Munich, Germany
| | - Stefanie M Hauck
- §Research Unit Protein Science, Helmholtz Zentrum München, Neuherberg, Germany
| | | | - Edda Kloppmann
- ¶Department of Informatics, Bioinformatics & Computational Biology i12, Technische Universität München, Garching/Munich, Germany; ‖New York Consortium on Membrane Protein Structure (NYCOMPS), New York Structural Biology Center, New York, New York 10027
| | - Tatyana Goldberg
- ¶Department of Informatics, Bioinformatics & Computational Biology i12, Technische Universität München, Garching/Munich, Germany; **TUM Graduate School, Center of Doctoral Studies in Informatics and its Applications (CeDoSIA), Technische Universität München, Munich, Germany
| | | | - Michael Schindler
- ‡‡Institute of Virology, Helmholtz Zentrum München, Neuherberg, Germany; §§Institute of Medical Virology and Epidemiology of Viral Diseases, University Clinic Tübingen, Tübingen, Germany
| | - Bettina Knapp
- ¶¶Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | - Linda Krause
- ¶¶Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany
| | - Katharina Dietz
- From the ‡Center of Allergy and Environment (ZAUM), Technische Universität und Helmholtz Zentrum München, Munich, Germany; ‖‖DZL- Member of the German Lung Research Center
| | - Carsten B Schmidt-Weber
- From the ‡Center of Allergy and Environment (ZAUM), Technische Universität und Helmholtz Zentrum München, Munich, Germany; ‖‖DZL- Member of the German Lung Research Center
| | - Kathrin Suttner
- From the ‡Center of Allergy and Environment (ZAUM), Technische Universität und Helmholtz Zentrum München, Munich, Germany; ‖‖DZL- Member of the German Lung Research Center
| |
Collapse
|